Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone.

Study Overview

• Status: Recruiting
• Conditions: Stage IV Renal Cell Cancer AJCC v8; Sarcomatoid Renal Cell Carcinoma; Stage IV Bladder Cancer AJCC v8; Stage IV Urethral Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8; Bladder Adenocarcinoma; Chromophobe Renal Cell Carcinoma; Papillary Renal Cell Carcinoma; Collecting Duct Carcinoma; Bladder Clear Cell Adenocarcinoma; Bladder Mixed Adenocarcinoma; Bladder Neuroendocrine Carcinoma; Bladder Small Cell Neuroendocrine Carcinoma; Bladder Squamous Cell Carcinoma; Kidney Medullary Carcinoma; Large Cell Neuroendocrine Carcinoma; Metastatic Bladder Carcinoma; Metastatic Bladder Large Cell Neuroendocrine Carcinoma; Metastatic Bladder Small Cell Neuroendocrine Carcinoma; Metastatic Bladder Squamous Cell Carcinoma; Metastatic Kidney Medullary Carcinoma; Metastatic Malignant Genitourinary System Neoplasm; Metastatic Penile Carcinoma; Metastatic Prostate Small Cell Neuroendocrine Carcinoma; Metastatic Sarcomatoid Renal Cell Carcinoma; Metastatic Urethral Carcinoma; Stage IV Penile Cancer AJCC v8; Urethral Clear Cell Adenocarcinoma; Urachal Adenocarcinoma; Metastatic Papillary Renal Cell Carcinoma; Invasive Bladder Giant Cell Urothelial Carcinoma; Invasive Bladder Lymphoepithelioma-Like Carcinoma; Invasive Bladder Nested Urothelial Carcinoma; Invasive Bladder Plasmacytoid Urothelial Carcinoma; Invasive Bladder Sarcomatoid Urothelial Carcinoma; Invasive Bladder Urothelial Carcinoma; Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma; Metastatic Bladder Lipid-Rich Urothelial Carcinoma; Metastatic Bladder Micropapillary Urothelial Carcinoma; Metastatic Bladder Plasmacytoid Urothelial Carcinoma; Metastatic Bladder Sarcomatoid Urothelial Carcinoma; Malignant Testicular Leydig Cell Tumor; Malignant Testicular Sertoli Cell Tumor; Metastatic Bladder Giant Cell Urothelial Carcinoma; Metastatic Chromophobe Renal Cell Carcinoma
• Intervention / Treatment: Biological: Nivolumab; Procedure: Magnetic Resonance Imaging; Biological: Ipilimumab; Procedure: Positron Emission Tomography; Drug: Cabozantinib S-malate; Procedure: Biospecimen Collection; Procedure: Bone Scan; Procedure: Computed Tomography; Procedure: Echocardiography Test

Detailed Description

PRIMARY OBJECTIVE:

I. To evaluate the efficacy of cabozantinib s-malate (cabozantinib) combined with nivolumab and ipilimumab in the first or second-line (and beyond) setting for patients within each of the rare genitourinary (GU) variant histology group of interest, as measured by objective response rate (ORR).

SECONDARY OBJECTIVES:

I. To estimate the progression-free survival (PFS) for patients treated with cabozantinib combined with nivolumab and ipilimumab within each rare variant histology.

II. To estimate the overall survival (OS) for patients treated with cabozantinib combined with nivolumab and ipilimumab within each rare variant histology.

III. To estimate the clinical benefit rate (defined as complete response [CR] or partial response [PR] or stable disease [SD]) for patients treated with cabozantinib combined with nivolumab and ipilimumab within each rare variant histology.

IV. To assess the safety of treating patients with rare variant histologies with cabozantinib combined with nivolumab and ipilimumab.

V. To support tissue banking and collection of clinical follow-up data for GU tract rare histological variants.

EXPLORATORY OBJECTIVE:

I. To assess effects of treatment in patients with bone-only disease by bone scan.

OUTLINE:

Patients receive cabozantinib orally (PO) once daily (QD) on days 1-21 of cycles 1-4 and on days 1-28 of subsequent cycles. Patients also receive nivolumab intravenously (IV) over 30 minutes on day 1 and ipilimumab IV over 90 minutes on day 1 of cycles 1-4. Patients then receive nivolumab IV over 30 minutes on day 1 of subsequent cycles. Treatment repeats every 21 days for cycles 1-4 and every 28 days for subsequent cycles for 2 years in the absence of disease progression or unacceptable toxicity. Patients may undergo echocardiography during screening and undergo computed tomography (CT) or magnetic resonance imaging (MRI), bone scan and blood and urine sample collection throughout the trial and may undergo positron emission tomography (PET)/CT throughout the trial.

After completion of study treatment, patients are followed up every 2 months for up to 5 years.

• Study Type: Interventional
• Enrollment (Estimated): 314
• Phase: Phase 2

Contacts and Locations

Study Locations

• Puerto Rico
  • San Juan, Puerto Rico, 00902
    • Active, not recruiting
    • Pan American Center for Oncology Trials LLC
• United States
  • Alabama
    • Birmingham, Alabama, United States, 35233
      • Active, not recruiting
      • University of Alabama at Birmingham Cancer Center
  • Alaska
    • Anchorage, Alaska, United States, 98508
      • Suspended
      • Anchorage Associates in Radiation Medicine
    • Anchorage, Alaska, United States, 99504
      • Suspended
      • Anchorage Radiation Therapy Center
    • Anchorage, Alaska, United States, 99508
      • Suspended
      • Alaska Breast Care and Surgery LLC
    • Anchorage, Alaska, United States, 99508
      • Suspended
      • Alaska Oncology and Hematology LLC
    • Anchorage, Alaska, United States, 99508
      • Suspended
      • Alaska Women's Cancer Care
    • Anchorage, Alaska, United States, 99508
      • Suspended
      • Anchorage Oncology Centre
    • Anchorage, Alaska, United States, 99508
      • Suspended
      • Katmai Oncology Group
    • Anchorage, Alaska, United States, 99508
      • Suspended
      • Providence Alaska Medical Center
  • Arizona
    • Kingman, Arizona, United States, 86401
      • Suspended
      • Kingman Regional Medical Center
    • Phoenix, Arizona, United States, 85054
      • Recruiting
      • Mayo Clinic Hospital in Arizona
      • Contact: Site Public Contact; Phone Number: 855-776-0015
      • Principal Investigator: Lance C. Pagliaro
    • Phoenix, Arizona, United States, 85004
      • Active, not recruiting
      • Cancer Center at Saint Joseph's
    • Scottsdale, Arizona, United States, 85259
      • Recruiting
      • Mayo Clinic in Arizona
      • Contact: Site Public Contact; Phone Number: 855-776-0015
      • Principal Investigator: Lance C. Pagliaro
    • Tucson, Arizona, United States, 85719
      • Active, not recruiting
      • Banner University Medical Center - Tucson
    • Tucson, Arizona, United States, 85719
      • Active, not recruiting
      • University of Arizona Cancer Center-North Campus
    • Tucson, Arizona, United States, 85704
      • Active, not recruiting
      • University of Arizona Cancer Center-Orange Grove Campus
  • Arkansas
    • Fort Smith, Arkansas, United States, 72903
      • Suspended
      • Mercy Hospital Fort Smith
    • Hot Springs, Arkansas, United States, 71913
      • Suspended
      • CHI Saint Vincent Cancer Center Hot Springs
  • California
    • Arroyo Grande, California, United States, 93420
      • Suspended
      • PCR Oncology
    • Arroyo Grande, California, United States, 93420
      • Active, not recruiting
      • Mission Hope Medical Oncology - Arroyo Grande
    • Burbank, California, United States, 91505
      • Suspended
      • Providence Saint Joseph Medical Center/Disney Family Cancer Center
    • Clovis, California, United States, 93611
      • Active, not recruiting
      • Community Cancer Institute
    • Clovis, California, United States, 93611
      • Active, not recruiting
      • University Oncology Associates
    • Dublin, California, United States, 94568
      • Active, not recruiting
      • Epic Care-Dublin
    • Emeryville, California, United States, 94608
      • Active, not recruiting
      • Bay Area Breast Surgeons Inc
    • Emeryville, California, United States, 94608
      • Active, not recruiting
      • Epic Care Partners in Cancer Care
    • Greenbrae, California, United States, 94904
      • Suspended
      • Marin Cancer Care Inc
    • Los Angeles, California, United States, 90033
      • Suspended
      • USC / Norris Comprehensive Cancer Center
    • Los Angeles, California, United States, 90020
      • Recruiting
      • Keck Medicine of USC Koreatown
      • Principal Investigator: Anishka D'Souza
      • Contact: Site Public Contact; Phone Number: 213-388-0908
    • Los Angeles, California, United States, 90033
      • Suspended
      • Los Angeles General Medical Center
    • Los Angeles, California, United States, 90095
      • Completed
      • UCLA / Jonsson Comprehensive Cancer Center
    • Martinez, California, United States, 94553-3156
      • Active, not recruiting
      • Contra Costa Regional Medical Center
    • Newport Beach, California, United States, 92663
      • Suspended
      • USC Norris Oncology/Hematology-Newport Beach
    • Oakland, California, United States, 94609
      • Suspended
      • Alta Bates Summit Medical Center - Summit Campus
    • Oakland, California, United States, 94609
      • Active, not recruiting
      • Bay Area Tumor Institute
    • San Luis Obispo, California, United States, 93401
      • Active, not recruiting
      • Pacific Central Coast Health Center-San Luis Obispo
    • Santa Maria, California, United States, 93444
      • Active, not recruiting
      • Mission Hope Medical Oncology - Santa Maria
    • Walnut Creek, California, United States, 94597
      • Active, not recruiting
      • Epic Care Cyberknife Center
  • Colorado
    • Colorado Springs, Colorado, United States, 80907
      • Active, not recruiting
      • Penrose-Saint Francis Healthcare
    • Colorado Springs, Colorado, United States, 80907
      • Active, not recruiting
      • Rocky Mountain Cancer Centers-Penrose
    • Denver, Colorado, United States, 80210
      • Suspended
      • AdventHealth Porter
    • Durango, Colorado, United States, 81301
      • Active, not recruiting
      • Mercy Medical Center
    • Durango, Colorado, United States, 81301
      • Active, not recruiting
      • CommonSpirit Cancer Center Mercy
    • Lakewood, Colorado, United States, 80228
      • Active, not recruiting
      • CommonSpirit Saint Anthony Hospital Cancer Center
    • Littleton, Colorado, United States, 80122
      • Suspended
      • AdventHealth Littleton
    • Longmont, Colorado, United States, 80501
      • Active, not recruiting
      • Longmont United Hospital
    • Longmont, Colorado, United States, 80501
      • Active, not recruiting
      • Rocky Mountain Cancer Centers-Longmont
    • Parker, Colorado, United States, 80138
      • Suspended
      • AdventHealth Parker
    • Pueblo, Colorado, United States, 81004
      • Active, not recruiting
      • Saint Mary Corwin Medical Center
  • District of Columbia
    • Washington D.C., District of Columbia, United States, 20007
      • Recruiting
      • MedStar Georgetown University Hospital
      • Contact: Site Public Contact; Phone Number: 202-444-2223
      • Principal Investigator: Nancy A. Dawson
  • Florida
    • Aventura, Florida, United States, 33180
      • Active, not recruiting
      • Mount Sinai Comprehensive Cancer Center at Aventura
    • Fort Lauderdale, Florida, United States, 33308
      • Recruiting
      • Holy Cross Hospital
      • Principal Investigator: Tareq Al baghdadi
      • Contact: Site Public Contact; Email: eileen.georgi@holy-cross.com
    • Miami Beach, Florida, United States, 33140
      • Active, not recruiting
      • Mount Sinai Medical Center
    • Orlando, Florida, United States, 32806
      • Recruiting
      • Orlando Health Cancer Institute
      • Contact: Site Public Contact; Phone Number: 321-841-7246; Email: CancerClinicalTrials@orlandohealth.com
      • Principal Investigator: Hatem Hassanein
  • Georgia
    • Atlanta, Georgia, United States, 30322
      • Recruiting
      • Emory University Hospital/Winship Cancer Institute
      • Contact: Site Public Contact; Phone Number: 404-778-1868
      • Principal Investigator: Mehmet A. Bilen
    • Atlanta, Georgia, United States, 30308
      • Recruiting
      • Emory University Hospital Midtown
      • Contact: Site Public Contact; Phone Number: 888-946-7447
      • Principal Investigator: Mehmet A. Bilen
    • Atlanta, Georgia, United States, 30342
      • Suspended
      • Emory Saint Joseph's Hospital
    • Johns Creek, Georgia, United States, 30097
      • Suspended
      • Emory Johns Creek Hospital
  • Idaho
    • Boise, Idaho, United States, 83706
      • Recruiting
      • Saint Alphonsus Cancer Care Center-Boise
      • Contact: Site Public Contact; Phone Number: 734-712-3671; Email: stephanie.couch@stjoeshealth.org
      • Principal Investigator: Tareq Al baghdadi
    • Boise, Idaho, United States, 83712
      • Suspended
      • Saint Luke's Cancer Institute - Boise
    • Caldwell, Idaho, United States, 83605
      • Recruiting
      • Saint Alphonsus Cancer Care Center-Caldwell
      • Contact: Site Public Contact; Phone Number: 734-712-3671; Email: stephanie.couch@stjoeshealth.org
      • Principal Investigator: Tareq Al baghdadi
    • Coeur d'Alene, Idaho, United States, 83814
      • Recruiting
      • Kootenai Health - Coeur d'Alene
      • Principal Investigator: John M. Schallenkamp
      • Contact: Site Public Contact; Phone Number: 406-969-6060; Email: mccinfo@mtcancer.org
    • Emmett, Idaho, United States, 83617
      • Suspended
      • Walter Knox Memorial Hospital
    • Fruitland, Idaho, United States, 83619
      • Suspended
      • Saint Luke's Cancer Institute - Fruitland
    • Meridian, Idaho, United States, 83642
      • Suspended
      • Idaho Urologic Institute-Meridian
    • Meridian, Idaho, United States, 83642
      • Suspended
      • Saint Luke's Cancer Institute - Meridian
    • Nampa, Idaho, United States, 83687
      • Recruiting
      • Saint Alphonsus Cancer Care Center-Nampa
      • Contact: Site Public Contact; Phone Number: 406-969-6060; Email: mccinfo@mtcancer.org
      • Principal Investigator: Tareq Al baghdadi
    • Nampa, Idaho, United States, 83687
      • Suspended
      • Saint Luke's Cancer Institute - Nampa
    • Post Falls, Idaho, United States, 83854
      • Recruiting
      • Kootenai Clinic Cancer Services - Post Falls
      • Principal Investigator: John M. Schallenkamp
      • Contact: Site Public Contact; Phone Number: 406-969-6060; Email: mccinfo@mtcancer.org
    • Sandpoint, Idaho, United States, 83864
      • Recruiting
      • Kootenai Clinic Cancer Services - Sandpoint
      • Principal Investigator: John M. Schallenkamp
      • Contact: Site Public Contact; Phone Number: 406-969-6060; Email: mccinfo@mtcancer.org
    • Twin Falls, Idaho, United States, 83301
      • Suspended
      • Saint Luke's Cancer Institute - Twin Falls
  • Illinois
    • Alton, Illinois, United States, 62002
      • Suspended
      • OSF Saint Anthony's Health Center
    • Aurora, Illinois, United States, 60504
      • Suspended
      • Rush-Copley Medical Center
    • Bloomington, Illinois, United States, 61704
      • Suspended
      • Illinois CancerCare-Bloomington
    • Burr Ridge, Illinois, United States, 60527
      • Suspended
      • Loyola Center for Health at Burr Ridge
    • Canton, Illinois, United States, 61520
      • Suspended
      • Illinois CancerCare-Canton
    • Carbondale, Illinois, United States, 62902
      • Suspended
      • Memorial Hospital of Carbondale
    • Carterville, Illinois, United States, 62918
      • Suspended
      • SIH Cancer Institute
    • Carthage, Illinois, United States, 62321
      • Suspended
      • Illinois CancerCare-Carthage
    • Chicago, Illinois, United States, 60612
      • Active, not recruiting
      • University of Illinois
    • Chicago, Illinois, United States, 60637
      • Recruiting
      • University of Chicago Comprehensive Cancer Center
      • Contact: Site Public Contact; Phone Number: 773-702-8222; Email: cancerclinicaltrials@bsd.uchicago.edu
      • Principal Investigator: Randy F. Sweis
    • Chicago, Illinois, United States, 60611
      • Active, not recruiting
      • Northwestern University
    • Chicago, Illinois, United States, 60612
      • Recruiting
      • Rush MD Anderson Cancer Center
      • Principal Investigator: Thomas C. Westbrook
      • Contact: Site Public Contact; Phone Number: 312-226-2371; Email: Cancer_Studies@rush.edu
    • Danville, Illinois, United States, 61832
      • Suspended
      • Carle at The Riverfront
    • Decatur, Illinois, United States, 62526
      • Recruiting
      • Cancer Care Specialists of Illinois - Decatur
      • Principal Investigator: Bryan A. Faller
      • Contact: Site Public Contact; Phone Number: 217-876-4762; Email: morganthaler.jodi@mhsil.com
    • Decatur, Illinois, United States, 62526
      • Suspended
      • Decatur Memorial Hospital
    • Dixon, Illinois, United States, 61021
      • Suspended
      • Illinois CancerCare-Dixon
    • Effingham, Illinois, United States, 62401
      • Recruiting
      • Crossroads Cancer Center
      • Principal Investigator: Bryan A. Faller
      • Contact: Site Public Contact; Phone Number: 217-876-4762; Email: morganthaler.jodi@mhsil.com
    • Effingham, Illinois, United States, 62401
      • Suspended
      • Carle Physician Group-Effingham
    • Eureka, Illinois, United States, 61530
      • Suspended
      • Illinois CancerCare-Eureka
    • Galesburg, Illinois, United States, 61401
      • Suspended
      • Western Illinois Cancer Treatment Center
    • Galesburg, Illinois, United States, 61401
      • Suspended
      • Illinois CancerCare-Galesburg
    • Homer Glen, Illinois, United States, 60491
      • Suspended
      • Loyola Medicine Homer Glen
    • Kewanee, Illinois, United States, 61443
      • Suspended
      • Illinois CancerCare-Kewanee Clinic
    • Lake Forest, Illinois, United States, 60045
      • Active, not recruiting
      • Northwestern Medicine Lake Forest Hospital
    • Macomb, Illinois, United States, 61455
      • Suspended
      • Illinois CancerCare-Macomb
    • Mattoon, Illinois, United States, 61938
      • Suspended
      • Carle Physician Group-Mattoon/Charleston
    • Maywood, Illinois, United States, 60153
      • Recruiting
      • Loyola University Medical Center
      • Contact: Site Public Contact; Phone Number: 708-226-4357
      • Principal Investigator: Joseph I. Clark
    • Melrose Park, Illinois, United States, 60160
      • Suspended
      • Marjorie Weinberg Cancer Center at Loyola-Gottlieb
    • Mount Vernon, Illinois, United States, 62864
      • Suspended
      • SSM Health Good Samaritan
    • New Lenox, Illinois, United States, 60451
      • Suspended
      • UC Comprehensive Cancer Center at Silver Cross
    • O'Fallon, Illinois, United States, 62269
      • Suspended
      • Cancer Care Center of O'Fallon
    • Oak Park, Illinois, United States, 60304
      • Recruiting
      • Rush MD Anderson Cancer Center at Rush Oak Park
      • Principal Investigator: Thomas C. Westbrook
      • Contact: Site Public Contact; Phone Number: 312-226-2371; Email: Cancer_Studies@rush.edu
    • Orland Park, Illinois, United States, 60462
      • Suspended
      • University of Chicago Medicine-Orland Park
    • Ottawa, Illinois, United States, 61350
      • Suspended
      • Illinois CancerCare-Ottawa Clinic
    • Pekin, Illinois, United States, 61554
      • Suspended
      • Illinois CancerCare-Pekin
    • Peoria, Illinois, United States, 61636
      • Suspended
      • Methodist Medical Center of Illinois
    • Peoria, Illinois, United States, 61615
      • Suspended
      • Illinois CancerCare-Peoria
    • Peru, Illinois, United States, 61354
      • Suspended
      • Valley Radiation Oncology
    • Peru, Illinois, United States, 61354
      • Suspended
      • Illinois CancerCare-Peru
    • Princeton, Illinois, United States, 61356
      • Suspended
      • Illinois CancerCare-Princeton
    • Shiloh, Illinois, United States, 62269
      • Recruiting
      • Memorial Hospital East
      • Contact: Site Public Contact; Phone Number: 314-747-9912; Email: dschwab@wustl.edu
      • Principal Investigator: Melissa A. Reimers
    • Springfield, Illinois, United States, 62702
      • Recruiting
      • Southern Illinois University School of Medicine
      • Principal Investigator: Bryan A. Faller
      • Contact: Site Public Contact; Phone Number: 217-545-7929
    • Springfield, Illinois, United States, 62702
      • Recruiting
      • Springfield Clinic
      • Principal Investigator: Bryan A. Faller
      • Contact: Site Public Contact; Phone Number: 800-444-7541
    • Springfield, Illinois, United States, 62781
      • Recruiting
      • Springfield Memorial Hospital
      • Principal Investigator: Bryan A. Faller
      • Contact: Site Public Contact; Phone Number: 217-528-7541; Email: pallante.beth@mhsil.com
    • Swansea, Illinois, United States, 62226
      • Suspended
      • Southwest Illinois Health Services LLP
    • Urbana, Illinois, United States, 61801
      • Suspended
      • The Carle Foundation Hospital
    • Urbana, Illinois, United States, 61801
      • Suspended
      • Carle Cancer Center
    • Washington, Illinois, United States, 61571
      • Suspended
      • Illinois CancerCare - Washington
    • Yorkville, Illinois, United States, 60560
      • Suspended
      • Rush-Copley Healthcare Center
  • Indiana
    • Richmond, Indiana, United States, 47374
      • Suspended
      • Reid Health
  • Iowa
    • Ames, Iowa, United States, 50010
      • Recruiting
      • Mary Greeley Medical Center
      • Principal Investigator: Joseph J. Merchant
      • Contact: Site Public Contact; Phone Number: 515-956-4132
    • Ames, Iowa, United States, 50010
      • Recruiting
      • McFarland Clinic - Ames
      • Principal Investigator: Joseph J. Merchant
      • Contact: Site Public Contact; Phone Number: 515-239-4734; Email: ksoder@mcfarlandclinic.com
    • Ankeny, Iowa, United States, 50023
      • Recruiting
      • UI Health Care Mission Cancer and Blood - Ankeny Clinic
      • Contact: Site Public Contact; Phone Number: 515-241-3305
      • Principal Investigator: Seema Harichand-Herdt
    • Bettendorf, Iowa, United States, 52722
      • Recruiting
      • University of Iowa Healthcare Cancer Services Quad Cities
      • Principal Investigator: Fernando Maciel Barbosa
      • Contact: Site Public Contact; Phone Number: 563-355-7733; Email: katherine-daprile@uiowa.edu
    • Boone, Iowa, United States, 50036
      • Suspended
      • McFarland Clinic - Boone
    • Clive, Iowa, United States, 50325
      • Suspended
      • Mercy Cancer Center-West Lakes
    • Clive, Iowa, United States, 50325
      • Recruiting
      • UI Health Care Mission Cancer and Blood - West Des Moines Clinic
      • Contact: Site Public Contact; Phone Number: 515-241-3305
      • Principal Investigator: Seema Harichand-Herdt
    • Council Bluffs, Iowa, United States, 51503
      • Active, not recruiting
      • Alegent Health Mercy Hospital
    • Creston, Iowa, United States, 50801
      • Suspended
      • Greater Regional Medical Center
    • Des Moines, Iowa, United States, 50314
      • Recruiting
      • Mercy Medical Center - Des Moines
      • Contact: Site Public Contact; Phone Number: 515-241-3305
      • Principal Investigator: Richard L. Deming
    • Des Moines, Iowa, United States, 50309
      • Recruiting
      • Iowa Methodist Medical Center
      • Contact: Site Public Contact; Phone Number: 515-241-6727
      • Principal Investigator: Seema Harichand-Herdt
    • Des Moines, Iowa, United States, 50309
      • Recruiting
      • UI Health Care Mission Cancer and Blood - Des Moines Clinic
      • Contact: Site Public Contact; Phone Number: 515-241-3305
      • Principal Investigator: Seema Harichand-Herdt
    • Des Moines, Iowa, United States, 50314
      • Recruiting
      • UI Health Care Mission Cancer and Blood - Laurel Clinic
      • Contact: Site Public Contact; Phone Number: 515-241-3305
      • Principal Investigator: Seema Harichand-Herdt
    • Fort Dodge, Iowa, United States, 50501
      • Recruiting
      • McFarland Clinic - Trinity Cancer Center
      • Principal Investigator: Joseph J. Merchant
      • Contact: Site Public Contact; Phone Number: 515-956-4132
    • Iowa City, Iowa, United States, 52242
      • Recruiting
      • University of Iowa/Holden Comprehensive Cancer Center
      • Principal Investigator: Fernando Maciel Barbosa
      • Contact: Site Public Contact; Phone Number: 800-237-1225
    • Jefferson, Iowa, United States, 50129
      • Suspended
      • McFarland Clinic - Jefferson
    • Marshalltown, Iowa, United States, 50158
      • Recruiting
      • McFarland Clinic - Marshalltown
      • Principal Investigator: Joseph J. Merchant
      • Contact: Site Public Contact; Phone Number: 515-956-4132
    • Waukee, Iowa, United States, 50263
      • Recruiting
      • UI Health Care Mission Cancer and Blood - Waukee Clinic
      • Contact: Site Public Contact; Phone Number: 515-241-3305
      • Principal Investigator: Seema Harichand-Herdt
    • West Des Moines, Iowa, United States, 50266
      • Suspended
      • Mercy Medical Center-West Lakes
  • Kansas
    • Chanute, Kansas, United States, 66720
      • Active, not recruiting
      • Cancer Center of Kansas - Chanute
    • Dodge City, Kansas, United States, 67801
      • Active, not recruiting
      • Cancer Center of Kansas - Dodge City
    • El Dorado, Kansas, United States, 67042
      • Active, not recruiting
      • Cancer Center of Kansas - El Dorado
    • Fairway, Kansas, United States, 66205
      • Suspended
      • University of Kansas Clinical Research Center
    • Garden City, Kansas, United States, 67846
      • Suspended
      • Central Care Cancer Center - Garden City
    • Great Bend, Kansas, United States, 67530
      • Suspended
      • Central Care Cancer Center - Great Bend
    • Hays, Kansas, United States, 67601
      • Recruiting
      • HaysMed
      • Contact: Site Public Contact; Phone Number: 785-623-5774
      • Principal Investigator: Elizabeth M. Wulff
    • Independence, Kansas, United States, 67301
      • Active, not recruiting
      • Cancer Center of Kansas-Independence
    • Kingman, Kansas, United States, 67068
      • Active, not recruiting
      • Cancer Center of Kansas-Kingman
    • Lawrence, Kansas, United States, 66044
      • Recruiting
      • Lawrence Memorial Hospital
      • Contact: Site Public Contact; Phone Number: 785-505-2800; Email: Stephanie.Norris@LMH.ORG
      • Principal Investigator: Elizabeth M. Wulff
    • Liberal, Kansas, United States, 67905
      • Active, not recruiting
      • Cancer Center of Kansas-Liberal
    • Manhattan, Kansas, United States, 66502
      • Active, not recruiting
      • Cancer Center of Kansas-Manhattan
    • McPherson, Kansas, United States, 67460
      • Active, not recruiting
      • Cancer Center of Kansas - McPherson
    • Newton, Kansas, United States, 67114
      • Active, not recruiting
      • Cancer Center of Kansas - Newton
    • Olathe, Kansas, United States, 66061
      • Recruiting
      • The University of Kansas Cancer Center - Olathe
      • Contact: Site Public Contact; Phone Number: 913-588-1569; Email: OlatheCCResearch@kumc.edu
      • Principal Investigator: Elizabeth M. Wulff
    • Parsons, Kansas, United States, 67357
      • Active, not recruiting
      • Cancer Center of Kansas - Parsons
    • Pittsburg, Kansas, United States, 66762
      • Recruiting
      • Freeman Physician Group of Pittsburg
      • Contact: Site Public Contact; Email: BNMathew@freemanhealth.com
      • Principal Investigator: Elizabeth M. Wulff
    • Pittsburg, Kansas, United States, 66762
      • Suspended
      • Mercy Hospital Pittsburg
    • Pratt, Kansas, United States, 67124
      • Active, not recruiting
      • Cancer Center of Kansas - Pratt
    • Salina, Kansas, United States, 67401
      • Recruiting
      • Salina Regional Health Center
      • Contact: Site Public Contact; Phone Number: 785-452-7038; Email: mleepers@srhc.com
      • Principal Investigator: Elizabeth M. Wulff
    • Salina, Kansas, United States, 67401
      • Active, not recruiting
      • Cancer Center of Kansas - Salina
    • Topeka, Kansas, United States, 66606
      • Recruiting
      • University of Kansas Health System Saint Francis Campus
      • Contact: Site Public Contact; Phone Number: 785-295-8000
      • Principal Investigator: Elizabeth M. Wulff
    • Wellington, Kansas, United States, 67152
      • Active, not recruiting
      • Cancer Center of Kansas - Wellington
    • Westwood, Kansas, United States, 66205
      • Recruiting
      • University of Kansas Hospital-Westwood Cancer Center
      • Contact: Site Public Contact; Phone Number: 913-588-3671; Email: KUCC_Navigation@kumc.edu
      • Principal Investigator: Elizabeth M. Wulff
    • Wichita, Kansas, United States, 67214
      • Active, not recruiting
      • Ascension Via Christi Hospitals Wichita
    • Wichita, Kansas, United States, 67214
      • Active, not recruiting
      • Cancer Center of Kansas - Wichita
    • Wichita, Kansas, United States, 67208
      • Active, not recruiting
      • Cancer Center of Kansas-Wichita Medical Arts Tower
    • Winfield, Kansas, United States, 67156
      • Active, not recruiting
      • Cancer Center of Kansas - Winfield
  • Kentucky
    • Bardstown, Kentucky, United States, 40004
      • Active, not recruiting
      • Flaget Memorial Hospital
    • Corbin, Kentucky, United States, 40701
      • Active, not recruiting
      • Commonwealth Cancer Center-Corbin
    • Lexington, Kentucky, United States, 40536
      • Recruiting
      • University of Kentucky/Markey Cancer Center
      • Contact: Site Public Contact; Phone Number: 859-257-3379
      • Principal Investigator: Zin W. Myint
    • Lexington, Kentucky, United States, 40504
      • Active, not recruiting
      • Saint Joseph Radiation Oncology Resource Center
    • Lexington, Kentucky, United States, 40509
      • Active, not recruiting
      • Saint Joseph Hospital East
    • London, Kentucky, United States, 40741
      • Active, not recruiting
      • Saint Joseph London
    • Louisville, Kentucky, United States, 40202
      • Suspended
      • Jewish Hospital
    • Louisville, Kentucky, United States, 40215
      • Suspended
      • Saints Mary and Elizabeth Hospital
    • Louisville, Kentucky, United States, 40245
      • Suspended
      • UofL Health Medical Center Northeast
    • Shepherdsville, Kentucky, United States, 40165
      • Suspended
      • Jewish Hospital Medical Center South
  • Louisiana
    • Baton Rouge, Louisiana, United States, 70836
      • Active, not recruiting
      • Ochsner High Grove
    • Baton Rouge, Louisiana, United States, 70809
      • Suspended
      • Hematology/Oncology Clinic PLLC
    • Kenner, Louisiana, United States, 70065
      • Active, not recruiting
      • Ochsner Medical Center Kenner
    • Metairie, Louisiana, United States, 70006
      • Active, not recruiting
      • LSU Healthcare Network / Metairie Multi-Specialty Clinic
    • Metairie, Louisiana, United States, 70006
      • Suspended
      • East Jefferson General Hospital
    • New Orleans, Louisiana, United States, 70112
      • Active, not recruiting
      • Louisiana State University Health Science Center
    • New Orleans, Louisiana, United States, 70121
      • Active, not recruiting
      • Ochsner Medical Center Jefferson
    • New Orleans, Louisiana, United States, 70112
      • Suspended
      • Tulane University School of Medicine
  • Maryland
    • Baltimore, Maryland, United States, 21204
      • Suspended
      • Greater Baltimore Medical Center
    • Bethesda, Maryland, United States, 20892
      • Recruiting
      • National Institutes of Health Clinical Center
      • Contact: Site Public Contact; Phone Number: 800-411-1222
      • Principal Investigator: Andrea B. Apolo
    • Frederick, Maryland, United States, 21702
      • Recruiting
      • FMH James M Stockman Cancer Institute
      • Principal Investigator: Patrick J. Mansky
      • Contact: Site Public Contact; Phone Number: 301-668-7043
  • Massachusetts
    • Burlington, Massachusetts, United States, 01805
      • Recruiting
      • Lahey Hospital and Medical Center
      • Contact: Site Public Contact; Phone Number: 781-744-3421; Email: lhmc-cancer-clinical-trials@lahey.org
      • Principal Investigator: Brendan Connell
    • Peabody, Massachusetts, United States, 01960
      • Recruiting
      • Lahey Medical Center-Peabody
      • Contact: Site Public Contact; Phone Number: 781-744-3421; Email: lhmc-cancer-clinical-trials@lahey.org
      • Principal Investigator: Brendan Connell
    • Springfield, Massachusetts, United States, 01104
      • Suspended
      • Mercy Medical Center
    • Winchester, Massachusetts, United States, 01890
      • Active, not recruiting
      • Beth Israel Deaconess Medical Center/Winchester Center for Cancer Care
  • Michigan
    • Ann Arbor, Michigan, United States, 48106
      • Recruiting
      • Trinity Health Saint Joseph Mercy Hospital Ann Arbor
      • Contact: Site Public Contact; Phone Number: 734-712-7251; Email: MCRCwebsitecontactform@stjoeshealth.org
      • Principal Investigator: Tareq Al baghdadi
    • Brighton, Michigan, United States, 48114
      • Recruiting
      • Trinity Health IHA Medical Group Hematology Oncology - Brighton
      • Contact: Site Public Contact; Phone Number: 734-712-7251; Email: MCRCwebsitecontactform@stjoeshealth.org
      • Principal Investigator: Tareq Al baghdadi
    • Brighton, Michigan, United States, 48114
      • Recruiting
      • Trinity Health Medical Center - Brighton
      • Contact: Site Public Contact; Phone Number: 734-712-7251; Email: MCRCwebsitecontactform@stjoeshealth.org
      • Principal Investigator: Tareq Al baghdadi
    • Brownstown, Michigan, United States, 48183
      • Recruiting
      • Henry Ford Cancer Institute-Downriver
      • Contact: Site Public Contact; Phone Number: 313-916-3721; Email: CTOResearch@hfhs.org
      • Principal Investigator: Haythem Y. Ali
    • Canton, Michigan, United States, 48188
      • Recruiting
      • Trinity Health IHA Medical Group Hematology Oncology - Canton
      • Contact: Site Public Contact; Phone Number: 734-712-7251; Email: MCRCwebsitecontactform@stjoeshealth.org
      • Principal Investigator: Tareq Al baghdadi
    • Canton, Michigan, United States, 48188
      • Recruiting
      • Trinity Health Medical Center - Canton
      • Contact: Site Public Contact; Phone Number: 734-712-7251; Email: MCRCwebsitecontactform@stjoeshealth.org
      • Principal Investigator: Tareq Al baghdadi
    • Caro, Michigan, United States, 48723
      • Suspended
      • Caro Cancer Center
    • Chelsea, Michigan, United States, 48118
      • Recruiting
      • Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
      • Contact: Site Public Contact; Phone Number: 734-712-7251; Email: MCRCwebsitecontactform@stjoeshealth.org
      • Principal Investigator: Tareq Al baghdadi
    • Chelsea, Michigan, United States, 48118
      • Recruiting
      • Chelsea Hospital
      • Contact: Site Public Contact; Phone Number: 734-712-7251; Email: MCRCwebsitecontactform@stjoeshealth.org
      • Principal Investigator: Tareq Al baghdadi
    • Clarkston, Michigan, United States, 48346
      • Recruiting
      • Hematology Oncology Consultants-Clarkston
      • Contact: Site Public Contact; Phone Number: 734-712-7251; Email: MCRCwebsitecontactform@stjoeshealth.org
      • Principal Investigator: Tareq Al baghdadi
    • Clarkston, Michigan, United States, 48346
      • Suspended
      • Newland Medical Associates-Clarkston
    • Clinton Township, Michigan, United States, 48038
      • Recruiting
      • Henry Ford Macomb Hospital-Clinton Township
      • Contact: Site Public Contact; Phone Number: 313-916-3721; Email: CTOResearch@hfhs.org
      • Principal Investigator: Haythem Y. Ali
    • Dearborn, Michigan, United States, 48126
      • Recruiting
      • Henry Ford Medical Center-Fairlane
      • Contact: Site Public Contact; Phone Number: 313-916-3721; Email: CTOResearch@hfhs.org
      • Principal Investigator: Haythem Y. Ali
    • Detroit, Michigan, United States, 48202
      • Recruiting
      • Henry Ford Hospital
      • Contact: Site Public Contact; Phone Number: 313-916-3721; Email: CTOResearch@hfhs.org
      • Principal Investigator: Haythem Y. Ali
    • Detroit, Michigan, United States, 48236
      • Recruiting
      • Henry Ford Health Saint John Hospital
      • Principal Investigator: Tareq Al baghdadi
      • Contact: Site Public Contact; Phone Number: 313-343-3166; Email: Kkeenan1@hfhs.org
    • East China Township, Michigan, United States, 48054
      • Recruiting
      • Henry Ford River District Hospital
      • Principal Investigator: Tareq Al baghdadi
      • Contact: Site Public Contact; Phone Number: 313-343-3166; Email: kforman1@hfhs.org
    • Flint, Michigan, United States, 48503
      • Recruiting
      • Genesys Hurley Cancer Institute
      • Contact: Site Public Contact; Phone Number: 810-762-8038; Email: wstrong@ghci.org
      • Principal Investigator: Tareq Al baghdadi
    • Flint, Michigan, United States, 48503
      • Recruiting
      • Hurley Medical Center
      • Contact: Site Public Contact; Phone Number: 810-762-8038; Email: wstrong@ghci.org
      • Principal Investigator: Tareq Al baghdadi
    • Flint, Michigan, United States, 48503
      • Suspended
      • Genesee Hematology Oncology PC
    • Flint, Michigan, United States, 48503
      • Recruiting
      • Cancer Hematology Centers - Flint
      • Contact: Site Public Contact; Phone Number: 810-762-8038; Email: wstrong@ghci.org
      • Principal Investigator: Tareq Al baghdadi
    • Grosse Pointe Woods, Michigan, United States, 48236
      • Suspended
      • Henry Ford Saint John Hospital - Breast
    • Grosse Pointe Woods, Michigan, United States, 48236
      • Recruiting
      • Henry Ford Saint John Hospital - Academic
      • Principal Investigator: Tareq Al baghdadi
      • Contact: Site Public Contact; Phone Number: 313-343-3166; Email: kforman1@hfhs.org
    • Grosse Pointe Woods, Michigan, United States, 48236
      • Recruiting
      • Henry Ford Saint John Hospital - Van Elslander
      • Principal Investigator: Tareq Al baghdadi
      • Contact: Site Public Contact; Phone Number: 313-343-3166; Email: kforman1@hfhs.org
    • Jackson, Michigan, United States, 49201
      • Recruiting
      • Allegiance Health
      • Contact: Site Public Contact; Phone Number: 313-916-3721; Email: CTOResearch@hfhs.org
      • Principal Investigator: Haythem Y. Ali
    • Lansing, Michigan, United States, 48912
      • Recruiting
      • University of Michigan Health - Sparrow Lansing
      • Principal Investigator: Tareq Al baghdadi
      • Contact: Site Public Contact; Phone Number: 517-364-3712; Email: harsha.trivedi@umhsparrow.org
    • Livonia, Michigan, United States, 48154
      • Suspended
      • Hope Cancer Clinic
    • Livonia, Michigan, United States, 48154
      • Recruiting
      • Trinity Health Saint Mary Mercy Livonia Hospital
      • Contact: Site Public Contact; Phone Number: 734-712-7251; Email: MCRCwebsitecontactform@stjoeshealth.org
      • Principal Investigator: Tareq Al baghdadi
    • Macomb, Michigan, United States, 48044
      • Suspended
      • Henry Ford Warren Hospital - Breast Macomb
    • Macomb, Michigan, United States, 48044
      • Recruiting
      • Henry Ford Saint John Hospital - Macomb Medical
      • Principal Investigator: Tareq Al baghdadi
      • Contact: Site Public Contact; Phone Number: 313-343-3166; Email: kforman1@hfhs.org
    • Marlette, Michigan, United States, 48453
      • Suspended
      • Saint Mary's Oncology/Hematology Associates of Marlette
    • Novi, Michigan, United States, 48377
      • Recruiting
      • Henry Ford Medical Center-Columbus
      • Contact: Site Public Contact; Phone Number: 313-916-3721; Email: CTOResearch@hfhs.org
      • Principal Investigator: Haythem Y. Ali
    • Pontiac, Michigan, United States, 48341
      • Recruiting
      • Newland Medical Associates-Pontiac
      • Contact: Site Public Contact; Phone Number: 734-712-7251; Email: MCRCwebsitecontactform@stjoeshealth.org
      • Principal Investigator: Tareq Al baghdadi
    • Pontiac, Michigan, United States, 48341
      • Suspended
      • Hope Cancer Center
    • Pontiac, Michigan, United States, 48341
      • Recruiting
      • Trinity Health Saint Joseph Mercy Oakland Hospital
      • Contact: Site Public Contact; Phone Number: 734-712-7251; Email: MCRCwebsitecontactform@stjoeshealth.org
      • Principal Investigator: Tareq Al baghdadi
    • Pontiac, Michigan, United States, 48341
      • Recruiting
      • Michigan Healthcare Professionals Pontiac
      • Principal Investigator: Tareq Al baghdadi
      • Contact: Site Public Contact; Phone Number: 248-858-6215; Email: Emily.Crofts@trinity-health.org
    • Port Huron, Michigan, United States, 48060
      • Suspended
      • Huron Medical Center PC
    • Port Huron, Michigan, United States, 48060
      • Suspended
      • Lake Huron Medical Center
    • Rochester Hills, Michigan, United States, 48309
      • Suspended
      • Henry Ford Rochester Hospital
    • Saginaw, Michigan, United States, 48604
      • Suspended
      • Oncology Hematology Associates of Saginaw Valley PC
    • Saginaw, Michigan, United States, 48601
      • Recruiting
      • MyMichigan Medical Center Saginaw
      • Contact: Site Public Contact; Phone Number: 734-712-7251; Email: MCRCwebsitecontactform@stjoeshealth.org
      • Principal Investigator: Tareq Al baghdadi
    • Shelby, Michigan, United States, 48315
      • Suspended
      • Henry Ford Macomb Health Center - Shelby Township
    • Sterling Heights, Michigan, United States, 48312
      • Suspended
      • Bhadresh Nayak MD PC-Sterling Heights
    • Tawas City, Michigan, United States, 48764
      • Recruiting
      • MyMichigan Medical Center Tawas
      • Contact: Site Public Contact; Phone Number: 734-712-7251; Email: MCRCwebsitecontactform@stjoeshealth.org
      • Principal Investigator: Tareq Al baghdadi
    • Warren, Michigan, United States, 48088
      • Suspended
      • Advanced Breast Care Center PLLC
    • Warren, Michigan, United States, 48093
      • Suspended
      • Macomb Hematology Oncology PC
    • Warren, Michigan, United States, 48093
      • Suspended
      • Henry Ford Madison Heights Hospital - Breast
    • Warren, Michigan, United States, 48093
      • Recruiting
      • Henry Ford Health Warren Hospital
      • Principal Investigator: Tareq Al baghdadi
      • Contact: Site Public Contact; Phone Number: 313-343-3166; Email: kforman1@hfhs.org
    • Warren, Michigan, United States, 48093
      • Recruiting
      • Henry Ford Warren Hospital - GLCMS
      • Principal Investigator: Tareq Al baghdadi
      • Contact: Site Public Contact; Phone Number: 313-343-3166; Email: kforman1@hfhs.org
    • West Bloomfield, Michigan, United States, 48322
      • Recruiting
      • Henry Ford West Bloomfield Hospital
      • Contact: Site Public Contact; Phone Number: 313-916-3721; Email: CTOResearch@hfhs.org
      • Principal Investigator: Haythem Y. Ali
    • West Branch, Michigan, United States, 48661
      • Suspended
      • Saint Mary's Oncology/Hematology Associates of West Branch
    • Wyandotte, Michigan, United States, 48192
      • Recruiting
      • Henry Ford Wyandotte Hospital
      • Principal Investigator: Haythem Y. Ali
      • Contact: Site Public Contact; Email: nhay@hfhs.org
    • Ypsilanti, Michigan, United States, 48106
      • Recruiting
      • Huron Gastroenterology PC
      • Contact: Site Public Contact; Phone Number: 734-712-7251; Email: MCRCwebsitecontactform@stjoeshealth.org
      • Principal Investigator: Tareq Al baghdadi
    • Ypsilanti, Michigan, United States, 48197
      • Recruiting
      • Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
      • Contact: Site Public Contact; Phone Number: 734-712-7251; Email: MCRCwebsitecontactform@stjoeshealth.org
      • Principal Investigator: Tareq Al baghdadi
  • Minnesota
    • Aitkin, Minnesota, United States, 56431
      • Suspended
      • Riverwood Healthcare Center
    • Brainerd, Minnesota, United States, 56401
      • Suspended
      • Essentia Health Saint Joseph's Medical Center
    • Burnsville, Minnesota, United States, 55337
      • Suspended
      • Fairview Ridges Hospital
    • Burnsville, Minnesota, United States, 55337
      • Suspended
      • Minnesota Oncology - Burnsville
    • Cambridge, Minnesota, United States, 55008
      • Suspended
      • Cambridge Medical Center
    • Coon Rapids, Minnesota, United States, 55433
      • Suspended
      • Mercy Hospital
    • Deer River, Minnesota, United States, 56636
      • Recruiting
      • Essentia Health - Deer River Clinic
      • Contact: Site Public Contact; Phone Number: 218-786-3308; Email: CancerTrials@EssentiaHealth.org
      • Principal Investigator: Bret E. Friday
    • Detroit Lakes, Minnesota, United States, 56501
      • Suspended
      • Essentia Health Saint Mary's - Detroit Lakes Clinic
    • Duluth, Minnesota, United States, 55805
      • Recruiting
      • Essentia Health Cancer Center
      • Contact: Site Public Contact; Phone Number: 218-786-3308; Email: CancerTrials@EssentiaHealth.org
      • Principal Investigator: Bret E. Friday
    • Duluth, Minnesota, United States, 55805
      • Suspended
      • Essentia Health Saint Mary's Medical Center
    • Duluth, Minnesota, United States, 55805
      • Suspended
      • Miller-Dwan Hospital
    • Edina, Minnesota, United States, 55435
      • Recruiting
      • Fairview Southdale Hospital
      • Contact: Site Public Contact; Phone Number: 952-993-1517; Email: mmcorc@healthpartners.com
      • Principal Investigator: Daniel M. Anderson
    • Fergus Falls, Minnesota, United States, 56537
      • Suspended
      • Lake Region Healthcare Corporation-Cancer Care
    • Fosston, Minnesota, United States, 56542
      • Suspended
      • Essentia Health - Fosston
    • Fridley, Minnesota, United States, 55432
      • Active, not recruiting
      • Unity Hospital
    • Hibbing, Minnesota, United States, 55746
      • Recruiting
      • Essentia Health Hibbing Clinic
      • Principal Investigator: Bret E. Friday
      • Contact: Site Public Contact; Phone Number: 218-786-3308
    • Maple Grove, Minnesota, United States, 55369
      • Suspended
      • Fairview Clinics and Surgery Center Maple Grove
    • Maplewood, Minnesota, United States, 55109
      • Suspended
      • Minnesota Oncology Hematology PA-Maplewood
    • Maplewood, Minnesota, United States, 55109
      • Suspended
      • Saint John's Hospital - Healtheast
    • Minneapolis, Minnesota, United States, 55415
      • Recruiting
      • Hennepin County Medical Center
      • Contact: Site Public Contact; Phone Number: 952-993-1517; Email: mmcorc@healthpartners.com
      • Principal Investigator: Daniel M. Anderson
    • Minneapolis, Minnesota, United States, 55407
      • Suspended
      • Abbott-Northwestern Hospital
    • Minneapolis, Minnesota, United States, 55454
      • Suspended
      • Health Partners Inc
    • Monticello, Minnesota, United States, 55362
      • Suspended
      • Monticello Cancer Center
    • New Ulm, Minnesota, United States, 56073
      • Suspended
      • New Ulm Medical Center
    • Park Rapids, Minnesota, United States, 56470
      • Suspended
      • Essentia Health - Park Rapids
    • Princeton, Minnesota, United States, 55371
      • Suspended
      • Fairview Northland Medical Center
    • Robbinsdale, Minnesota, United States, 55422
      • Suspended
      • North Memorial Medical Health Center
    • Rochester, Minnesota, United States, 55905
      • Recruiting
      • Mayo Clinic in Rochester
      • Contact: Site Public Contact; Phone Number: 855-776-0015
      • Principal Investigator: Lance C. Pagliaro
    • Saint Louis Park, Minnesota, United States, 55416
      • Suspended
      • Park Nicollet Clinic - Saint Louis Park
    • Saint Paul, Minnesota, United States, 55101
      • Recruiting
      • Regions Hospital
      • Contact: Site Public Contact; Phone Number: 952-993-1517; Email: mmcorc@healthpartners.com
      • Principal Investigator: Daniel M. Anderson
    • Saint Paul, Minnesota, United States, 55102
      • Suspended
      • United Hospital
    • Sandstone, Minnesota, United States, 55072
      • Recruiting
      • Essentia Health Sandstone
      • Contact: Site Public Contact; Phone Number: 218-786-3308; Email: CancerTrials@EssentiaHealth.org
      • Principal Investigator: Bret E. Friday
    • Shakopee, Minnesota, United States, 55379
      • Suspended
      • Saint Francis Regional Medical Center
    • Stillwater, Minnesota, United States, 55082
      • Recruiting
      • Lakeview Hospital
      • Contact: Site Public Contact; Phone Number: 952-993-1517; Email: mmcorc@healthpartners.com
      • Principal Investigator: Daniel M. Anderson
    • Virginia, Minnesota, United States, 55792
      • Recruiting
      • Essentia Health Virginia Clinic
      • Contact: Site Public Contact; Phone Number: 218-786-3308; Email: CancerTrials@EssentiaHealth.org
      • Principal Investigator: Bret E. Friday
    • Waconia, Minnesota, United States, 55387
      • Recruiting
      • Ridgeview Medical Center
      • Contact: Site Public Contact; Phone Number: 952-993-1517; Email: mmcorc@healthpartners.com
      • Principal Investigator: Daniel M. Anderson
    • Willmar, Minnesota, United States, 56201
      • Suspended
      • Rice Memorial Hospital
    • Woodbury, Minnesota, United States, 55125
      • Suspended
      • Minnesota Oncology Hematology PA-Woodbury
    • Wyoming, Minnesota, United States, 55092
      • Suspended
      • Fairview Lakes Medical Center
  • Mississippi
    • Jackson, Mississippi, United States, 39216
      • Recruiting
      • University of Mississippi Medical Center
      • Contact: Site Public Contact; Phone Number: 601-815-6700
      • Principal Investigator: John C. Henegan
  • Missouri
    • Ballwin, Missouri, United States, 63011
      • Suspended
      • Mercy Oncology and Hematology - Clayton-Clarkson
    • Bolivar, Missouri, United States, 65613
      • Suspended
      • Central Care Cancer Center - Bolivar
    • Bonne Terre, Missouri, United States, 63628
      • Suspended
      • Parkland Health Center-Bonne Terre
    • Branson, Missouri, United States, 65616
      • Suspended
      • Cox Cancer Center Branson
    • Cape Girardeau, Missouri, United States, 63703
      • Recruiting
      • Saint Francis Medical Center
      • Principal Investigator: Bryan A. Faller
      • Contact: Site Public Contact; Phone Number: 573-334-2230; Email: sfmc@sfmc.net
    • Cape Girardeau, Missouri, United States, 63703
      • Suspended
      • Mercy Cancer Center - Cape Girardeau
    • City of Saint Peters, Missouri, United States, 63376
      • Recruiting
      • Siteman Cancer Center at Saint Peters Hospital
      • Contact: Site Public Contact; Phone Number: 800-600-3606; Email: info@siteman.wustl.edu
      • Principal Investigator: Melissa A. Reimers
    • Creve Coeur, Missouri, United States, 63141
      • Recruiting
      • Siteman Cancer Center at West County Hospital
      • Contact: Site Public Contact; Phone Number: 800-600-3606; Email: info@siteman.wustl.edu
      • Principal Investigator: Melissa A. Reimers
    • Farmington, Missouri, United States, 63640
      • Recruiting
      • Parkland Health Center - Farmington
      • Principal Investigator: Bryan A. Faller
      • Contact: Site Public Contact; Phone Number: 314-996-5569
    • Jefferson City, Missouri, United States, 65109
      • Suspended
      • MU Health Care Goldschmidt Cancer Center
    • Joplin, Missouri, United States, 64804
      • Suspended
      • Freeman Health System
    • Joplin, Missouri, United States, 64804
      • Suspended
      • Mercy Hospital Joplin
    • Kansas City, Missouri, United States, 64108
      • Recruiting
      • University Health Truman Medical Center
      • Contact: Site Public Contact; Phone Number: 816-404-4375
      • Principal Investigator: Elizabeth M. Wulff
    • Lee's Summit, Missouri, United States, 64064
      • Recruiting
      • University of Kansas Cancer Center - Lee's Summit
      • Contact: Site Public Contact; Phone Number: 913-588-3671; Email: KUCC_Navigation@kumc.edu
      • Principal Investigator: Elizabeth M. Wulff
    • Rolla, Missouri, United States, 65401
      • Suspended
      • Mercy Clinic-Rolla-Cancer and Hematology
    • Rolla, Missouri, United States, 65401
      • Suspended
      • Phelps Health Delbert Day Cancer Institute
    • Saint Joseph, Missouri, United States, 64506
      • Suspended
      • Heartland Regional Medical Center
    • Sainte Genevieve, Missouri, United States, 63670
      • Recruiting
      • Sainte Genevieve County Memorial Hospital
      • Principal Investigator: Bryan A. Faller
      • Contact: Site Public Contact; Phone Number: 314-996-5569
    • Springfield, Missouri, United States, 65804
      • Suspended
      • Mercy Hospital Springfield
    • Springfield, Missouri, United States, 65807
      • Suspended
      • CoxHealth South Hospital
    • St Louis, Missouri, United States, 63110
      • Recruiting
      • Washington University School of Medicine
      • Contact: Site Public Contact; Phone Number: 800-600-3606; Email: info@siteman.wustl.edu
      • Principal Investigator: Melissa A. Reimers
    • St Louis, Missouri, United States, 63128
      • Recruiting
      • Mercy Hospital South
      • Principal Investigator: Jay W. Carlson
      • Contact: Site Public Contact; Phone Number: 314-525-6042; Email: Danielle.Werle@mercy.net
    • St Louis, Missouri, United States, 63141
      • Recruiting
      • Mercy Hospital Saint Louis
      • Principal Investigator: Jay W. Carlson
      • Contact: Site Public Contact; Phone Number: 314-251-7066
    • St Louis, Missouri, United States, 63129
      • Recruiting
      • Siteman Cancer Center-South County
      • Contact: Site Public Contact; Phone Number: 800-600-3606; Email: info@siteman.wustl.edu
      • Principal Investigator: Melissa A. Reimers
    • St Louis, Missouri, United States, 63136
      • Recruiting
      • Siteman Cancer Center at Christian Hospital
      • Contact: Site Public Contact; Phone Number: 800-600-3606; Email: info@siteman.wustl.edu
      • Principal Investigator: Melissa A. Reimers
    • St Louis, Missouri, United States, 63109
      • Suspended
      • Mercy Infusion Center - Chippewa
    • St Louis, Missouri, United States, 63131
      • Recruiting
      • Missouri Baptist Medical Center
      • Principal Investigator: Bryan A. Faller
      • Contact: Site Public Contact; Phone Number: 314-996-5569
    • Sullivan, Missouri, United States, 63080
      • Recruiting
      • Missouri Baptist Sullivan Hospital
      • Principal Investigator: Bryan A. Faller
      • Contact: Site Public Contact; Phone Number: 314-996-5569
    • Sunset Hills, Missouri, United States, 63127
      • Recruiting
      • BJC Outpatient Center at Sunset Hills
      • Principal Investigator: Bryan A. Faller
      • Contact: Site Public Contact; Phone Number: 314-996-5569
    • Washington, Missouri, United States, 63090
      • Suspended
      • Mercy Hospital Washington
  • Montana
    • Anaconda, Montana, United States, 59711
      • Recruiting
      • Community Hospital of Anaconda
      • Principal Investigator: John M. Schallenkamp
      • Contact: Site Public Contact; Phone Number: 406-969-6060; Email: mccinfo@mtcancer.org
    • Billings, Montana, United States, 59101
      • Recruiting
      • Billings Clinic Cancer Center
      • Principal Investigator: John M. Schallenkamp
      • Contact: Site Public Contact; Phone Number: 800-996-2663; Email: research@billingsclinic.org
    • Bozeman, Montana, United States, 59715
      • Recruiting
      • Bozeman Health Deaconess Hospital
      • Principal Investigator: John M. Schallenkamp
      • Contact: Site Public Contact; Phone Number: 406-969-6060; Email: mccinfo@mtcancer.org
    • Great Falls, Montana, United States, 59405
      • Suspended
      • Great Falls Clinic
    • Great Falls, Montana, United States, 59405
      • Recruiting
      • Benefis Sletten Cancer Institute
      • Principal Investigator: John M. Schallenkamp
      • Contact: Site Public Contact; Phone Number: 406-969-6060; Email: mccinfo@mtcancer.org
    • Helena, Montana, United States, 59601
      • Suspended
      • Saint Peter's Community Hospital
    • Kalispell, Montana, United States, 59901
      • Recruiting
      • Logan Health Medical Center
      • Principal Investigator: John M. Schallenkamp
      • Contact: Site Public Contact; Phone Number: 406-969-6060; Email: mccinfo@mtcancer.org
    • Missoula, Montana, United States, 59802
      • Suspended
      • Saint Patrick Hospital - Community Hospital
    • Missoula, Montana, United States, 59804
      • Recruiting
      • Community Medical Center
      • Principal Investigator: John M. Schallenkamp
      • Contact: Site Public Contact; Phone Number: 406-969-6060; Email: mccinfo@mtcancer.org
  • Nebraska
    • Bellevue, Nebraska, United States, 68123
      • Recruiting
      • Nebraska Medicine-Bellevue
      • Contact: Site Public Contact; Phone Number: 402-559-6941; Email: unmcrsa@unmc.edu
      • Principal Investigator: Benjamin A. Teply
    • Grand Island, Nebraska, United States, 68803
      • Suspended
      • Nebraska Cancer Specialists/Oncology Hematology West PC
    • Kearney, Nebraska, United States, 68847
      • Active, not recruiting
      • CHI Health Good Samaritan
    • Lincoln, Nebraska, United States, 68510
      • Active, not recruiting
      • Saint Elizabeth Regional Medical Center
    • Omaha, Nebraska, United States, 68198
      • Recruiting
      • University of Nebraska Medical Center
      • Contact: Site Public Contact; Phone Number: 402-559-6941; Email: unmcrsa@unmc.edu
      • Principal Investigator: Benjamin A. Teply
    • Omaha, Nebraska, United States, 68118
      • Recruiting
      • Nebraska Medicine-Village Pointe
      • Contact: Site Public Contact; Phone Number: 402-559-5600
      • Principal Investigator: Benjamin A. Teply
    • Omaha, Nebraska, United States, 68122
      • Active, not recruiting
      • Alegent Health Immanuel Medical Center
    • Omaha, Nebraska, United States, 68124
      • Active, not recruiting
      • Alegent Health Bergan Mercy Medical Center
    • Omaha, Nebraska, United States, 68130
      • Active, not recruiting
      • Alegent Health Lakeside Hospital
    • Omaha, Nebraska, United States, 68131
      • Active, not recruiting
      • Creighton University Medical Center
    • Omaha, Nebraska, United States, 68114
      • Suspended
      • Nebraska Methodist Hospital
    • Omaha, Nebraska, United States, 68114
      • Suspended
      • Nebraska Cancer Specialists/Oncology Hematology West PC - MECC
    • Omaha, Nebraska, United States, 68114
      • Suspended
      • Oncology Associates PC
    • Papillion, Nebraska, United States, 68046
      • Active, not recruiting
      • Midlands Community Hospital
  • Nevada
    • Carson City, Nevada, United States, 89703
      • Suspended
      • Carson Tahoe Regional Medical Center
    • Henderson, Nevada, United States, 89052
      • Suspended
      • Cancer and Blood Specialists-Henderson
    • Henderson, Nevada, United States, 89052
      • Suspended
      • Comprehensive Cancer Centers of Nevada - Henderson
    • Henderson, Nevada, United States, 89052
      • Suspended
      • Comprehensive Cancer Centers of Nevada-Horizon Ridge
    • Henderson, Nevada, United States, 89052
      • Suspended
      • Las Vegas Cancer Center-Henderson
    • Henderson, Nevada, United States, 89074
      • Suspended
      • Comprehensive Cancer Centers of Nevada-Southeast Henderson
    • Henderson, Nevada, United States, 89074
      • Suspended
      • Las Vegas Urology - Green Valley
    • Henderson, Nevada, United States, 89074
      • Suspended
      • Las Vegas Urology - Pebble
    • Henderson, Nevada, United States, 89074
      • Suspended
      • Urology Specialists of Nevada - Green Valley
    • Henderson, Nevada, United States, 89074
      • Suspended
      • Oncology Las Vegas - Henderson
    • Las Vegas, Nevada, United States, 89102
      • Suspended
      • Desert West Surgery
    • Las Vegas, Nevada, United States, 89102
      • Recruiting
      • OptumCare Cancer Care at Charleston
      • Contact: Site Public Contact; Phone Number: 702-384-0013; Email: research@sncrf.org
      • Principal Investigator: John A. Ellerton
    • Las Vegas, Nevada, United States, 89106
      • Suspended
      • Cancer and Blood Specialists-Shadow
    • Las Vegas, Nevada, United States, 89109
      • Suspended
      • HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway
    • Las Vegas, Nevada, United States, 89113
      • Suspended
      • HealthCare Partners Medical Group Oncology/Hematology-San Martin
    • Las Vegas, Nevada, United States, 89128
      • Suspended
      • Cancer and Blood Specialists-Tenaya
    • Las Vegas, Nevada, United States, 89128
      • Suspended
      • HealthCare Partners Medical Group Oncology/Hematology-Tenaya
    • Las Vegas, Nevada, United States, 89149
      • Suspended
      • HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills
    • Las Vegas, Nevada, United States, 89074
      • Suspended
      • Las Vegas Urology - Pecos
    • Las Vegas, Nevada, United States, 89102
      • Suspended
      • University Medical Center of Southern Nevada
    • Las Vegas, Nevada, United States, 89103
      • Suspended
      • Hope Cancer Care of Nevada
    • Las Vegas, Nevada, United States, 89106
      • Suspended
      • Radiation Oncology Centers of Nevada Central
    • Las Vegas, Nevada, United States, 89106
      • Suspended
      • Urology Specialists of Nevada - Central
    • Las Vegas, Nevada, United States, 89109
      • Suspended
      • Sunrise Hospital and Medical Center
    • Las Vegas, Nevada, United States, 89113
      • Suspended
      • Las Vegas Prostate Cancer Center
    • Las Vegas, Nevada, United States, 89113
      • Suspended
      • Las Vegas Urology - Sunset
    • Las Vegas, Nevada, United States, 89113
      • Suspended
      • Urology Specialists of Nevada - Southwest
    • Las Vegas, Nevada, United States, 89119
      • Suspended
      • Radiation Oncology Centers of Nevada Southeast
    • Las Vegas, Nevada, United States, 89128
      • Suspended
      • Ann M Wierman MD LTD
    • Las Vegas, Nevada, United States, 89128
      • Suspended
      • Comprehensive Cancer Centers of Nevada - Northwest
    • Las Vegas, Nevada, United States, 89128
      • Suspended
      • Las Vegas Urology - Cathedral Rock
    • Las Vegas, Nevada, United States, 89128
      • Suspended
      • Las Vegas Urology - Smoke Ranch
    • Las Vegas, Nevada, United States, 89128
      • Suspended
      • OptumCare Cancer Care at MountainView
    • Las Vegas, Nevada, United States, 89128
      • Suspended
      • Urology Specialists of Nevada - Northwest
    • Las Vegas, Nevada, United States, 89135
      • Suspended
      • Alliance for Childhood Diseases/Cure 4 the Kids Foundation
    • Las Vegas, Nevada, United States, 89144
      • Suspended
      • Comprehensive Cancer Centers of Nevada - Town Center
    • Las Vegas, Nevada, United States, 89144
      • Suspended
      • Comprehensive Cancer Centers of Nevada-Summerlin
    • Las Vegas, Nevada, United States, 89144
      • Suspended
      • Summerlin Hospital Medical Center
    • Las Vegas, Nevada, United States, 89148-2405
      • Suspended
      • Las Vegas Cancer Center-Medical Center
    • Las Vegas, Nevada, United States, 89148
      • Suspended
      • Comprehensive Cancer Centers of Nevada
    • Las Vegas, Nevada, United States, 89169
      • Suspended
      • Comprehensive Cancer Centers of Nevada - Central Valley
    • Las Vegas, Nevada, United States, 89169
      • Suspended
      • University Cancer Center
    • Las Vegas, Nevada, United States, 89128
      • Suspended
      • Oncology Las Vegas - Tenaya
    • Las Vegas, Nevada, United States, 89183
      • Recruiting
      • OptumCare Cancer Care at Fort Apache
      • Contact: Site Public Contact; Phone Number: 702-384-0013; Email: research@sncrf.org
      • Principal Investigator: John A. Ellerton
    • Pahrump, Nevada, United States, 89048
      • Suspended
      • Hope Cancer Care of Nevada-Pahrump
    • Reno, Nevada, United States, 89502
      • Suspended
      • Renown Regional Medical Center
    • Reno, Nevada, United States, 89503
      • Suspended
      • Saint Mary's Regional Medical Center
    • Reno, Nevada, United States, 89509
      • Suspended
      • Radiation Oncology Associates
  • New Jersey
    • Basking Ridge, New Jersey, United States, 07920
      • Recruiting
      • Memorial Sloan Kettering Basking Ridge
      • Contact: Site Public Contact; Phone Number: 212-639-7592
      • Principal Investigator: Samuel A. Funt
    • Middletown, New Jersey, United States, 07748
      • Recruiting
      • Memorial Sloan Kettering Monmouth
      • Contact: Site Public Contact; Phone Number: 212-639-7592
      • Principal Investigator: Samuel A. Funt
    • Montvale, New Jersey, United States, 07645
      • Recruiting
      • Memorial Sloan Kettering Bergen
      • Contact: Site Public Contact; Phone Number: 212-639-7592
      • Principal Investigator: Samuel A. Funt
  • New York
    • Brooklyn, New York, United States, 11219
      • Active, not recruiting
      • Maimonides Medical Center
    • Brooklyn, New York, United States, 11215
      • Active, not recruiting
      • New York-Presbyterian/Brooklyn Methodist Hospital
    • Buffalo, New York, United States, 14263
      • Active, not recruiting
      • Roswell Park Cancer Institute
    • Commack, New York, United States, 11725
      • Recruiting
      • Memorial Sloan Kettering Commack
      • Contact: Site Public Contact; Phone Number: 212-639-7592
      • Principal Investigator: Samuel A. Funt
    • Harrison, New York, United States, 10604
      • Recruiting
      • Memorial Sloan Kettering Westchester
      • Contact: Site Public Contact; Phone Number: 212-639-7592
      • Principal Investigator: Samuel A. Funt
    • Lake Success, New York, United States, 11042
      • Active, not recruiting
      • Northwell Health/Center for Advanced Medicine
    • Mineola, New York, United States, 11501
      • Recruiting
      • NYU Langone Hospital - Long Island
      • Contact: Site Public Contact; Phone Number: 212-263-4432; Email: cancertrials@nyulangone.org
      • Principal Investigator: David R. Wise
    • New York, New York, United States, 10032
      • Recruiting
      • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
      • Principal Investigator: Mark N. Stein
      • Contact: Site Public Contact; Phone Number: 212-342-5162; Email: cancerclinicaltrials@cumc.columbia.edu
    • New York, New York, United States, 10065
      • Recruiting
      • Memorial Sloan Kettering Cancer Center
      • Contact: Site Public Contact; Phone Number: 212-639-7592
      • Principal Investigator: Samuel A. Funt
    • New York, New York, United States, 10065
      • Recruiting
      • NYP/Weill Cornell Medical Center
      • Contact: Site Public Contact; Phone Number: 212-746-1848
      • Principal Investigator: Cora N. Sternberg
    • New York, New York, United States, 10016
      • Suspended
      • Laura and Isaac Perlmutter Cancer Center at NYU Langone
    • Rochester, New York, United States, 14642
      • Active, not recruiting
      • University of Rochester
    • Syracuse, New York, United States, 13210
      • Active, not recruiting
      • State University of New York Upstate Medical University
    • Uniondale, New York, United States, 11553
      • Recruiting
      • Memorial Sloan Kettering Nassau
      • Contact: Site Public Contact; Phone Number: 212-639-7592
      • Principal Investigator: Samuel A. Funt
  • North Carolina
    • Chapel Hill, North Carolina, United States, 27599
      • Recruiting
      • UNC Lineberger Comprehensive Cancer Center
      • Contact: Site Public Contact; Phone Number: 877-668-0683; Email: cancerclinicaltrials@med.unc.edu
      • Principal Investigator: Tracy L. Rose
    • Hendersonville, North Carolina, United States, 28791
      • Recruiting
      • Margaret R Pardee Memorial Hospital
      • Contact: Site Public Contact; Phone Number: 828-696-4716; Email: pardeecancerresearch@unchealth.unc.edu
      • Principal Investigator: John K. Hill
  • North Dakota
    • Fargo, North Dakota, United States, 58103
      • Suspended
      • Essentia Health Cancer Center-South University Clinic
    • Jamestown, North Dakota, United States, 58401
      • Suspended
      • Essentia Health - Jamestown Clinic
  • Ohio
    • Beavercreek, Ohio, United States, 45431
      • Suspended
      • Indu and Raj Soin Medical Center
    • Belpre, Ohio, United States, 45714
      • Recruiting
      • Strecker Cancer Center-Belpre
      • Contact: Site Public Contact; Phone Number: 614-488-2745; Email: Jeffh@columbusccop.org
      • Principal Investigator: Aruna C. Gowda
    • Boardman, Ohio, United States, 44512
      • Suspended
      • Saint Elizabeth Boardman Hospital
    • Centerville, Ohio, United States, 45459
      • Active, not recruiting
      • Miami Valley Hospital South
    • Centerville, Ohio, United States, 45459
      • Suspended
      • Dayton Physicians LLC-Miami Valley South
    • Chillicothe, Ohio, United States, 45601
      • Recruiting
      • Adena Regional Medical Center
      • Contact: Site Public Contact; Phone Number: 877-779-7585; Email: Jeffh@columbusccop.org
      • Principal Investigator: Aruna C. Gowda
    • Cincinnati, Ohio, United States, 45236
      • Suspended
      • Oncology Hematology Care Inc-Kenwood
    • Cincinnati, Ohio, United States, 45219
      • Active, not recruiting
      • University of Cincinnati Cancer Center-UC Medical Center
    • Cincinnati, Ohio, United States, 45220
      • Active, not recruiting
      • Good Samaritan Hospital - Cincinnati
    • Cincinnati, Ohio, United States, 45242
      • Active, not recruiting
      • Bethesda North Hospital
    • Cincinnati, Ohio, United States, 45247
      • Active, not recruiting
      • TriHealth Cancer Institute-Westside
    • Cincinnati, Ohio, United States, 45255
      • Active, not recruiting
      • TriHealth Cancer Institute-Anderson
    • Columbus, Ohio, United States, 43213
      • Recruiting
      • Mount Carmel East Hospital
      • Contact: Site Public Contact; Phone Number: 614-488-2745; Email: Jeffh@columbusccop.org
      • Principal Investigator: Aruna C. Gowda
    • Columbus, Ohio, United States, 43214
      • Recruiting
      • Columbus Oncology and Hematology Associates Inc
      • Contact: Site Public Contact; Phone Number: 614-788-3860; Email: Jennifer.Sexton@ohiohealth.com
      • Principal Investigator: Shakir Sarwar
    • Columbus, Ohio, United States, 43214
      • Recruiting
      • Riverside Methodist Hospital
      • Contact: Site Public Contact; Phone Number: 614-788-3860; Email: Jennifer.Sexton@ohiohealth.com
      • Principal Investigator: Shakir Sarwar
    • Columbus, Ohio, United States, 43215
      • Recruiting
      • Grant Medical Center
      • Contact: Site Public Contact; Phone Number: 614-788-3860; Email: Jennifer.Sexton@ohiohealth.com
      • Principal Investigator: Shakir Sarwar
    • Columbus, Ohio, United States, 43219
      • Recruiting
      • The Mark H Zangmeister Center
      • Contact: Site Public Contact; Phone Number: 614-488-2745; Email: Jeffh@columbusccop.org
      • Principal Investigator: Aruna C. Gowda
    • Columbus, Ohio, United States, 43222
      • Recruiting
      • Mount Carmel Health Center West
      • Contact: Site Public Contact; Phone Number: 614-488-2745; Email: Jeffh@columbusccop.org
      • Principal Investigator: Aruna C. Gowda
    • Columbus, Ohio, United States, 43228
      • Recruiting
      • Doctors Hospital
      • Contact: Site Public Contact; Phone Number: 614-788-3860; Email: Jennifer.Sexton@ohiohealth.com
      • Principal Investigator: Shakir Sarwar
    • Columbus, Ohio, United States, 43210
      • Recruiting
      • Ohio State University Comprehensive Cancer Center
      • Contact: Site Public Contact; Phone Number: 800-293-5066; Email: Jamesline@osumc.edu
      • Principal Investigator: Amir Mortazavi
    • Dayton, Ohio, United States, 45406
      • Suspended
      • Good Samaritan Hospital - Dayton
    • Dayton, Ohio, United States, 45409
      • Active, not recruiting
      • Miami Valley Hospital
    • Dayton, Ohio, United States, 45415
      • Active, not recruiting
      • Miami Valley Hospital North
    • Dayton, Ohio, United States, 45415
      • Suspended
      • Dayton Physician LLC - Englewood
    • Delaware, Ohio, United States, 43015
      • Recruiting
      • Delaware Health Center-Grady Cancer Center
      • Contact: Site Public Contact; Phone Number: 614-788-3860; Email: Jennifer.Sexton@ohiohealth.com
      • Principal Investigator: Shakir Sarwar
    • Delaware, Ohio, United States, 43015
      • Recruiting
      • Grady Memorial Hospital
      • Contact: Site Public Contact; Phone Number: 614-788-3860; Email: Jennifer.Sexton@ohiohealth.com
      • Principal Investigator: Shakir Sarwar
    • Dublin, Ohio, United States, 43016
      • Suspended
      • Dublin Methodist Hospital
    • Findlay, Ohio, United States, 45840
      • Suspended
      • Blanchard Valley Hospital
    • Findlay, Ohio, United States, 45840
      • Suspended
      • Orion Cancer Care
    • Findlay, Ohio, United States, 45840
      • Suspended
      • Armes Family Cancer Center
    • Franklin, Ohio, United States, 45005-1066
      • Suspended
      • Atrium Medical Center-Middletown Regional Hospital
    • Franklin, Ohio, United States, 45005
      • Suspended
      • Dayton Physicians LLC-Atrium
    • Gahanna, Ohio, United States, 43230
      • Suspended
      • Central Ohio Breast and Endocrine Surgery
    • Greenville, Ohio, United States, 45331
      • Suspended
      • Dayton Physicians LLC-Wayne
    • Greenville, Ohio, United States, 45331
      • Suspended
      • Wayne Hospital
    • Grove City, Ohio, United States, 43123
      • Suspended
      • Mount Carmel Grove City Hospital
    • Kettering, Ohio, United States, 45429
      • Recruiting
      • Kettering Medical Center
      • Contact: Site Public Contact; Phone Number: 937-528-2900; Email: clinical.trials@daytonncorp.org
      • Principal Investigator: Howard M. Gross
    • Kettering, Ohio, United States, 45420
      • Suspended
      • First Dayton Cancer Care
    • Kettering, Ohio, United States, 45409
      • Suspended
      • Greater Dayton Cancer Center
    • Lancaster, Ohio, United States, 43130
      • Recruiting
      • Fairfield Medical Center
      • Contact: Site Public Contact; Phone Number: 614-488-2745; Email: Jeffh@columbusccop.org
      • Principal Investigator: Aruna C. Gowda
    • Lima, Ohio, United States, 45801
      • Suspended
      • Saint Rita's Medical Center
    • Mansfield, Ohio, United States, 44903
      • Recruiting
      • OhioHealth Mansfield Hospital
      • Contact: Site Public Contact; Phone Number: 614-788-3860; Email: Jennifer.Sexton@ohiohealth.com
      • Principal Investigator: Shakir Sarwar
    • Marietta, Ohio, United States, 45750
      • Recruiting
      • Marietta Memorial Hospital
      • Contact: Site Public Contact; Phone Number: 614-488-2745; Email: Jeffh@columbusccop.org
      • Principal Investigator: Aruna C. Gowda
    • Marion, Ohio, United States, 43302
      • Recruiting
      • OhioHealth Marion General Hospital
      • Contact: Site Public Contact; Phone Number: 614-788-3860; Email: Jennifer.Sexton@ohiohealth.com
      • Principal Investigator: Shakir Sarwar
    • Marysville, Ohio, United States, 43040
      • Recruiting
      • Memorial Hospital
      • Contact: Site Public Contact; Phone Number: 614-488-2745; Email: Jeffh@columbusccop.org
      • Principal Investigator: Aruna C. Gowda
    • Mount Vernon, Ohio, United States, 43050
      • Recruiting
      • Knox Community Hospital
      • Contact: Site Public Contact; Phone Number: 614-488-2745; Email: Jeffh@columbusccop.org
      • Principal Investigator: Aruna C. Gowda
    • Newark, Ohio, United States, 43055
      • Recruiting
      • Licking Memorial Hospital
      • Contact: Site Public Contact; Phone Number: 614-488-2745; Email: Jeffh@columbusccop.org
      • Principal Investigator: Aruna C. Gowda
    • Newark, Ohio, United States, 43055
      • Suspended
      • Newark Radiation Oncology
    • Perrysburg, Ohio, United States, 43551
      • Suspended
      • Mercy Health - Perrysburg Hospital
    • Portsmouth, Ohio, United States, 45662
      • Recruiting
      • Southern Ohio Medical Center
      • Contact: Site Public Contact; Phone Number: 614-488-2745; Email: Jeffh@columbusccop.org
      • Principal Investigator: Aruna C. Gowda
    • Springfield, Ohio, United States, 45504
      • Recruiting
      • Springfield Regional Cancer Center
      • Contact: Site Public Contact; Phone Number: 614-488-2745; Email: Jeffh@columbusccop.org
      • Principal Investigator: Aruna C. Gowda
    • Springfield, Ohio, United States, 45504
      • Suspended
      • Springfield Regional Medical Center
    • Toledo, Ohio, United States, 43623
      • Suspended
      • Mercy Health - Saint Anne Hospital
    • Toledo, Ohio, United States, 43608
      • Suspended
      • Mercy Health - Saint Vincent Hospital
    • Troy, Ohio, United States, 45373
      • Suspended
      • Upper Valley Medical Center
    • Troy, Ohio, United States, 45373
      • Suspended
      • Dayton Physicians LLC - Troy
    • Warren, Ohio, United States, 44484
      • Suspended
      • Saint Joseph Warren Hospital
    • West Chester, Ohio, United States, 45069
      • Active, not recruiting
      • University of Cincinnati Cancer Center-West Chester
    • Westerville, Ohio, United States, 43081
      • Recruiting
      • Saint Ann's Hospital
      • Contact: Site Public Contact; Phone Number: 614-488-2745; Email: Jeffh@columbusccop.org
      • Principal Investigator: Aruna C. Gowda
    • Youngstown, Ohio, United States, 44501
      • Suspended
      • Saint Elizabeth Youngstown Hospital
    • Zanesville, Ohio, United States, 43701
      • Recruiting
      • Genesis Healthcare System Cancer Care Center
      • Contact: Site Public Contact; Phone Number: 614-488-2745; Email: Jeffh@columbusccop.org
      • Principal Investigator: Aruna C. Gowda
  • Oklahoma
    • Lawton, Oklahoma, United States, 73505
      • Recruiting
      • Cancer Centers of Southwest Oklahoma Research
      • Contact: Site Public Contact; Phone Number: 877-231-4440
      • Principal Investigator: Adanma Anji Ayanambakkam Attanathi
    • Oklahoma City, Oklahoma, United States, 73104
      • Recruiting
      • University of Oklahoma Health Sciences Center
      • Contact: Site Public Contact; Phone Number: 405-271-8777; Email: ou-clinical-trials@ouhsc.edu
      • Principal Investigator: Adanma Anji Ayanambakkam Attanathi
    • Oklahoma City, Oklahoma, United States, 73120
      • Suspended
      • Mercy Hospital Oklahoma City
    • Tulsa, Oklahoma, United States, 74146
      • Suspended
      • Oklahoma Cancer Specialists and Research Institute-Tulsa
  • Oregon
    • Baker City, Oregon, United States, 97814
      • Suspended
      • Saint Alphonsus Cancer Care Center-Baker City
    • Bend, Oregon, United States, 97701
      • Suspended
      • Saint Charles Health System
    • Clackamas, Oregon, United States, 97015
      • Suspended
      • Clackamas Radiation Oncology Center
    • Clackamas, Oregon, United States, 97015
      • Suspended
      • Providence Cancer Institute Clackamas Clinic
    • Coos Bay, Oregon, United States, 97420
      • Suspended
      • Bay Area Hospital
    • Newberg, Oregon, United States, 97132
      • Recruiting
      • Providence Newberg Medical Center
      • Principal Investigator: Alison K. Conlin
      • Contact: Site Public Contact; Phone Number: 503-215-2614; Email: CanRsrchStudies@providence.org
    • Ontario, Oregon, United States, 97914
      • Recruiting
      • Saint Alphonsus Cancer Care Center-Ontario
      • Contact: Site Public Contact; Phone Number: 406-969-6060; Email: mccinfo@mtcancer.org
      • Principal Investigator: Tareq Al baghdadi
    • Oregon City, Oregon, United States, 97045
      • Recruiting
      • Providence Willamette Falls Medical Center
      • Principal Investigator: Alison K. Conlin
      • Contact: Site Public Contact; Phone Number: 503-215-2614; Email: CanRsrchStudies@providence.org
    • Portland, Oregon, United States, 97239
      • Recruiting
      • Oregon Health and Science University
      • Contact: Site Public Contact; Phone Number: 503-494-1080; Email: trials@ohsu.edu
      • Principal Investigator: Christopher W. Ryan
    • Portland, Oregon, United States, 97213
      • Recruiting
      • Providence Portland Medical Center
      • Principal Investigator: Alison K. Conlin
      • Contact: Site Public Contact; Phone Number: 503-215-2614; Email: CanRsrchStudies@providence.org
    • Portland, Oregon, United States, 97225
      • Recruiting
      • Providence Saint Vincent Medical Center
      • Principal Investigator: Alison K. Conlin
      • Contact: Site Public Contact; Phone Number: 503-215-2614; Email: CanRsrchStudies@providence.org
    • Redmond, Oregon, United States, 97756
      • Suspended
      • Saint Charles Health System-Redmond
  • Pennsylvania
    • Allentown, Pennsylvania, United States, 18103
      • Recruiting
      • Lehigh Valley Hospital-Cedar Crest
      • Contact: Site Public Contact; Phone Number: 610-402-9543; Email: Morgan_M.Horton@lvhn.org
      • Principal Investigator: Tareq Al baghdadi
    • Bethlehem, Pennsylvania, United States, 18017
      • Recruiting
      • Lehigh Valley Hospital - Muhlenberg
      • Contact: Site Public Contact; Phone Number: 610-402-9543; Email: Morgan_M.Horton@lvhn.org
      • Principal Investigator: Tareq Al baghdadi
    • East Stroudsburg, Pennsylvania, United States, 18301
      • Recruiting
      • Pocono Medical Center
      • Contact: Site Public Contact; Phone Number: 610-402-9543; Email: Morgan_M.Horton@lvhn.org
      • Principal Investigator: Tareq Al baghdadi
    • Erie, Pennsylvania, United States, 16505
      • Recruiting
      • UPMC Hillman Cancer Center Erie
      • Principal Investigator: Leonard J. Appleman
      • Contact: Site Public Contact; Phone Number: 412-864-7716; Email: ClinicalResearchServices@upmc.edu
    • Erie, Pennsylvania, United States, 16544
      • Active, not recruiting
      • Saint Vincent Hospital
    • Greensburg, Pennsylvania, United States, 15601
      • Recruiting
      • UPMC Cancer Centers - Arnold Palmer Pavilion
      • Contact: Site Public Contact; Phone Number: 724-838-1900
      • Principal Investigator: Leonard J. Appleman
    • Hazleton, Pennsylvania, United States, 18201
      • Recruiting
      • Lehigh Valley Hospital-Hazleton
      • Contact: Site Public Contact; Phone Number: 610-402-9543; Email: Morgan_M.Horton@lvhn.org
      • Principal Investigator: Tareq Al baghdadi
    • Jefferson Hills, Pennsylvania, United States, 15025
      • Active, not recruiting
      • Jefferson Hospital
    • Monroeville, Pennsylvania, United States, 15146
      • Recruiting
      • UPMC Hillman Cancer Center - Monroeville
      • Principal Investigator: Leonard J. Appleman
      • Contact: Site Public Contact; Phone Number: 412-864-7716; Email: ClinicalResearchServices@upmc.edu
    • Monroeville, Pennsylvania, United States, 15146
      • Active, not recruiting
      • UPMC Cancer Center - Monroeville
    • Monroeville, Pennsylvania, United States, 15146
      • Active, not recruiting
      • Forbes Hospital
    • N. Huntingdon, Pennsylvania, United States, 15642
      • Recruiting
      • Arnold Palmer Cancer Center Medical Oncology Norwin
      • Principal Investigator: Leonard J. Appleman
      • Contact: Site Public Contact; Phone Number: 412-864-7716; Email: ClinicalResearchServices@upmc.edu
    • Natrona Heights, Pennsylvania, United States, 15065
      • Active, not recruiting
      • Allegheny Valley Hospital
    • Pittsburgh, Pennsylvania, United States, 15232
      • Recruiting
      • University of Pittsburgh Cancer Institute (UPCI)
      • Contact: Site Public Contact; Phone Number: 412-647-8073
      • Principal Investigator: Leonard J. Appleman
    • Pittsburgh, Pennsylvania, United States, 15232
      • Active, not recruiting
      • UPMC-Shadyside Hospital
    • Pittsburgh, Pennsylvania, United States, 15237
      • Recruiting
      • UPMC-Passavant Hospital
      • Contact: Site Public Contact; Phone Number: 412-367-6454
      • Principal Investigator: Leonard J. Appleman
    • Pittsburgh, Pennsylvania, United States, 15243
      • Recruiting
      • UPMC-Saint Clair Hospital Cancer Center
      • Contact: Site Public Contact; Phone Number: 412-502-3920
      • Principal Investigator: Leonard J. Appleman
    • Pittsburgh, Pennsylvania, United States, 15224
      • Active, not recruiting
      • West Penn Hospital
    • Pittsburgh, Pennsylvania, United States, 15212
      • Active, not recruiting
      • Allegheny General Hospital
    • Wexford, Pennsylvania, United States, 15090
      • Active, not recruiting
      • Wexford Health and Wellness Pavilion
  • South Carolina
    • Charleston, South Carolina, United States, 29425
      • Recruiting
      • Medical University of South Carolina
      • Contact: Site Public Contact; Phone Number: 843-792-9321; Email: hcc-clinical-trials@musc.edu
      • Principal Investigator: Theodore S. Gourdin
  • Tennessee
    • Alcoa, Tennessee, United States, 37701
      • Active, not recruiting
      • University Cancer Specialists - Alcoa
    • Franklin, Tennessee, United States, 37067
      • Suspended
      • Vanderbilt-Ingram Cancer Center Cool Springs
    • Knoxville, Tennessee, United States, 37920
      • Active, not recruiting
      • University of Tennessee - Knoxville
    • Nashville, Tennessee, United States, 37232
      • Recruiting
      • Vanderbilt University/Ingram Cancer Center
      • Principal Investigator: Kerry R. Schaffer
      • Contact: Site Public Contact; Phone Number: 800-811-8480
    • Nashville, Tennessee, United States, 37204
      • Suspended
      • Vanderbilt Breast Center at One Hundred Oaks
  • Texas
    • Bryan, Texas, United States, 77802
      • Active, not recruiting
      • Saint Joseph Regional Cancer Center
    • Dallas, Texas, United States, 75390
      • Recruiting
      • UT Southwestern/Simmons Cancer Center-Dallas
      • Contact: Site Public Contact; Phone Number: 214-648-7097; Email: canceranswerline@UTSouthwestern.edu
      • Principal Investigator: Suzanne M. Cole
    • Dallas, Texas, United States, 75237
      • Recruiting
      • UT Southwestern Simmons Cancer Center - RedBird
      • Contact: Site Public Contact; Phone Number: 214-648-7097; Email: canceranswerline@UTSouthwestern.edu
      • Principal Investigator: Suzanne M. Cole
    • Fort Worth, Texas, United States, 76104
      • Recruiting
      • UT Southwestern/Simmons Cancer Center-Fort Worth
      • Contact: Site Public Contact; Phone Number: 214-648-7097; Email: canceranswerline@UTSouthwestern.edu
      • Principal Investigator: Suzanne M. Cole
    • Richardson, Texas, United States, 75080
      • Recruiting
      • UT Southwestern Clinical Center at Richardson/Plano
      • Contact: Site Public Contact; Phone Number: 972-669-7044; Email: Suzanne.cole@utsouthwestern.edu
      • Principal Investigator: Suzanne M. Cole
  • Washington
    • Aberdeen, Washington, United States, 98520
      • Suspended
      • Providence Regional Cancer System-Aberdeen
    • Bellevue, Washington, United States, 98004
      • Suspended
      • Overlake Medical Center
    • Bellingham, Washington, United States, 98225
      • Suspended
      • PeaceHealth Saint Joseph Medical Center
    • Burien, Washington, United States, 98166
      • Active, not recruiting
      • Highline Medical Center-Main Campus
    • Centralia, Washington, United States, 98531
      • Suspended
      • Providence Regional Cancer System-Centralia
    • Edmonds, Washington, United States, 98026
      • Suspended
      • Swedish Cancer Institute-Edmonds
    • Enumclaw, Washington, United States, 98022
      • Active, not recruiting
      • Saint Elizabeth Hospital
    • Everett, Washington, United States, 98201
      • Suspended
      • Providence Regional Cancer Partnership
    • Federal Way, Washington, United States, 98003
      • Active, not recruiting
      • Saint Francis Hospital
    • Issaquah, Washington, United States, 98029
      • Suspended
      • Swedish Cancer Institute-Issaquah
    • Kennewick, Washington, United States, 99336
      • Recruiting
      • Kadlec Clinic Hematology and Oncology
      • Principal Investigator: Alison K. Conlin
      • Contact: Site Public Contact; Phone Number: 509-783-4637; Email: research@kadlecmed.org
    • Lacey, Washington, United States, 98503
      • Suspended
      • Providence Regional Cancer System-Lacey
    • Lakewood, Washington, United States, 98499
      • Active, not recruiting
      • Saint Clare Hospital
    • Longview, Washington, United States, 98632
      • Suspended
      • PeaceHealth Saint John Medical Center
    • Poulsbo, Washington, United States, 98370
      • Active, not recruiting
      • Harrison HealthPartners Hematology and Oncology-Poulsbo
    • Renton, Washington, United States, 98055
      • Recruiting
      • Valley Medical Center
      • Principal Investigator: John A. Ellerton
      • Contact: Site Public Contact; Phone Number: 425-228-3440; Email: research@valleymed.org
    • Seattle, Washington, United States, 98104
      • Suspended
      • Pacific Gynecology Specialists
    • Seattle, Washington, United States, 98107
      • Suspended
      • Swedish Medical Center-Ballard Campus
    • Seattle, Washington, United States, 98122-5711
      • Suspended
      • Swedish Medical Center-Cherry Hill
    • Seattle, Washington, United States, 98122
      • Suspended
      • Swedish Medical Center-First Hill
    • Sedro-Woolley, Washington, United States, 98284
      • Suspended
      • PeaceHealth United General Medical Center
    • Shelton, Washington, United States, 98584
      • Suspended
      • Providence Regional Cancer System-Shelton
    • Silverdale, Washington, United States, 98383
      • Active, not recruiting
      • Saint Joseph Medical Center Hematology and Oncology - Silverdale
    • Tacoma, Washington, United States, 98405
      • Suspended
      • Northwest Medical Specialties PLLC
    • Tacoma, Washington, United States, 98405
      • Active, not recruiting
      • Franciscan Research Center-Northwest Medical Plaza
    • Vancouver, Washington, United States, 98664
      • Suspended
      • PeaceHealth Southwest Medical Center
    • Walla Walla, Washington, United States, 99362
      • Suspended
      • Providence Saint Mary Regional Cancer Center
    • Yakima, Washington, United States, 98902
      • Suspended
      • North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
    • Yelm, Washington, United States, 98597
      • Suspended
      • Providence Regional Cancer System-Yelm
  • Wisconsin
    • Ashland, Wisconsin, United States, 54806
      • Recruiting
      • Duluth Clinic Ashland
      • Contact: Site Public Contact; Phone Number: 218-786-3308; Email: CancerTrials@EssentiaHealth.org
      • Principal Investigator: Bret E. Friday
    • Ashland, Wisconsin, United States, 54806
      • Suspended
      • Northwest Wisconsin Cancer Center
    • Burlington, Wisconsin, United States, 53105
      • Recruiting
      • Aurora Cancer Care-Southern Lakes VLCC
      • Contact: Site Public Contact; Phone Number: 414-302-2304; Email: ncorp@aurora.org
      • Principal Investigator: Thomas J. Saphner
    • Cudahy, Wisconsin, United States, 53110
      • Suspended
      • Aurora Saint Luke's South Shore
    • Eau Claire, Wisconsin, United States, 54701
      • Recruiting
      • Marshfield Medical Center-EC Cancer Center
      • Contact: Site Public Contact; Phone Number: 800-782-8581; Email: oncology.clinical.trials@marshfieldresearch.org
      • Principal Investigator: Michael Husak
    • Eau Claire, Wisconsin, United States, 54701
      • Recruiting
      • Mayo Clinic Health System-Eau Claire Clinic
      • Contact: Site Public Contact; Phone Number: 855-776-0015
      • Principal Investigator: Lance C. Pagliaro
    • Germantown, Wisconsin, United States, 53022
      • Recruiting
      • Aurora Health Care Germantown Health Center
      • Contact: Site Public Contact; Phone Number: 414-302-2304; Email: ncorp@aurora.org
      • Principal Investigator: Thomas J. Saphner
    • Grafton, Wisconsin, United States, 53024
      • Recruiting
      • Aurora Cancer Care-Grafton
      • Contact: Site Public Contact; Phone Number: 414-302-2304; Email: ncorp@aurora.org
      • Principal Investigator: Thomas J. Saphner
    • Green Bay, Wisconsin, United States, 54311
      • Recruiting
      • Aurora BayCare Medical Center
      • Contact: Site Public Contact; Phone Number: 414-302-2304; Email: ncorp@aurora.org
      • Principal Investigator: Thomas J. Saphner
    • Kenosha, Wisconsin, United States, 53142
      • Recruiting
      • Aurora Cancer Care-Kenosha South
      • Contact: Site Public Contact; Phone Number: 414-302-2304; Email: ncorp@aurora.org
      • Principal Investigator: Thomas J. Saphner
    • Marinette, Wisconsin, United States, 54143
      • Recruiting
      • Aurora Bay Area Medical Group-Marinette
      • Contact: Site Public Contact; Phone Number: 414-302-2304; Email: ncorp@aurora.org
      • Principal Investigator: Thomas J. Saphner
    • Marshfield, Wisconsin, United States, 54449
      • Recruiting
      • Marshfield Medical Center-Marshfield
      • Contact: Site Public Contact; Phone Number: 800-782-8581; Email: oncology.clinical.trials@marshfieldresearch.org
      • Principal Investigator: Michael Husak
    • Milwaukee, Wisconsin, United States, 53209
      • Recruiting
      • Aurora Cancer Care-Milwaukee
      • Contact: Site Public Contact; Phone Number: 414-302-2304; Email: ncorp@aurora.org
      • Principal Investigator: Thomas J. Saphner
    • Milwaukee, Wisconsin, United States, 53215
      • Recruiting
      • Aurora Saint Luke's Medical Center
      • Contact: Site Public Contact; Phone Number: 414-302-2304; Email: ncorp@aurora.org
      • Principal Investigator: Thomas J. Saphner
    • Milwaukee, Wisconsin, United States, 53233
      • Recruiting
      • Aurora Sinai Medical Center
      • Contact: Site Public Contact; Phone Number: 414-302-2304; Email: ncorp@aurora.org
      • Principal Investigator: Thomas J. Saphner
    • Minocqua, Wisconsin, United States, 54548
      • Recruiting
      • Marshfield Medical Center - Minocqua
      • Contact: Site Public Contact; Phone Number: 800-782-8581; Email: oncology.clinical.trials@marshfieldresearch.org
      • Principal Investigator: Michael Husak
    • Mukwonago, Wisconsin, United States, 53149
      • Recruiting
      • ProHealth D N Greenwald Center
      • Contact: Site Public Contact; Email: research.institute@phci.org
      • Principal Investigator: Timothy R. Wassenaar
    • New Richmond, Wisconsin, United States, 54017
      • Suspended
      • Cancer Center of Western Wisconsin
    • Oconomowoc, Wisconsin, United States, 53066
      • Recruiting
      • ProHealth Oconomowoc Memorial Hospital
      • Principal Investigator: Timothy R. Wassenaar
      • Contact: Site Public Contact; Phone Number: 262-928-7878
    • Oshkosh, Wisconsin, United States, 54904
      • Recruiting
      • Vince Lombardi Cancer Clinic - Oshkosh
      • Contact: Site Public Contact; Phone Number: 414-302-2304; Email: ncorp@aurora.org
      • Principal Investigator: Thomas J. Saphner
    • Racine, Wisconsin, United States, 53406
      • Recruiting
      • Aurora Cancer Care-Racine
      • Contact: Site Public Contact; Phone Number: 414-302-2304; Email: ncorp@aurora.org
      • Principal Investigator: Thomas J. Saphner
    • Rice Lake, Wisconsin, United States, 54868
      • Recruiting
      • Marshfield Medical Center-Rice Lake
      • Contact: Site Public Contact; Phone Number: 800-782-8581; Email: oncology.clinical.trials@marshfieldresearch.org
      • Principal Investigator: Michael Husak
    • Sheboygan, Wisconsin, United States, 53081
      • Recruiting
      • Vince Lombardi Cancer Clinic-Sheboygan
      • Contact: Site Public Contact; Phone Number: 414-302-2304; Email: ncorp@aurora.org
      • Principal Investigator: Thomas J. Saphner
    • Stevens Point, Wisconsin, United States, 54482
      • Recruiting
      • Marshfield Medical Center-River Region at Stevens Point
      • Contact: Site Public Contact; Phone Number: 800-782-8581; Email: oncology.clinical.trials@marshfieldresearch.org
      • Principal Investigator: Michael Husak
    • Summit, Wisconsin, United States, 53066
      • Recruiting
      • Aurora Medical Center in Summit
      • Contact: Site Public Contact; Phone Number: 414-302-2304; Email: ncorp@aurora.org
      • Principal Investigator: Thomas J. Saphner
    • Two Rivers, Wisconsin, United States, 54241
      • Recruiting
      • Vince Lombardi Cancer Clinic-Two Rivers
      • Contact: Site Public Contact; Phone Number: 414-302-2304; Email: ncorp@aurora.org
      • Principal Investigator: Thomas J. Saphner
    • Waukesha, Wisconsin, United States, 53188
      • Recruiting
      • ProHealth Waukesha Memorial Hospital
      • Principal Investigator: Timothy R. Wassenaar
      • Contact: Site Public Contact; Phone Number: 262-928-7632
    • Waukesha, Wisconsin, United States, 53188
      • Recruiting
      • UW Cancer Center at ProHealth Care
      • Principal Investigator: Timothy R. Wassenaar
      • Contact: Site Public Contact; Phone Number: 262-928-5539; Email: Chanda.miller@phci.org
    • Wauwatosa, Wisconsin, United States, 53226
      • Recruiting
      • Aurora Cancer Care-Milwaukee West
      • Contact: Site Public Contact; Phone Number: 414-302-2304; Email: ncorp@aurora.org
      • Principal Investigator: Thomas J. Saphner
    • West Allis, Wisconsin, United States, 53227
      • Recruiting
      • Aurora West Allis Medical Center
      • Contact: Site Public Contact; Phone Number: 414-302-2304; Email: ncorp@aurora.org
      • Principal Investigator: Thomas J. Saphner
    • Weston, Wisconsin, United States, 54476
      • Recruiting
      • Marshfield Medical Center - Weston
      • Contact: Site Public Contact; Phone Number: 800-782-8581; Email: oncology.clinical.trials@marshfieldresearch.org
      • Principal Investigator: Michael Husak
  • Wyoming
    • Cody, Wyoming, United States, 82414
      • Suspended
      • Billings Clinic-Cody
    • Sheridan, Wyoming, United States, 82801
      • Suspended
      • Welch Cancer Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Metastatic disease defined as new or progressive lesions on cross-sectional imaging or bone scan. Patients must have at least:

  • One measurable site of disease as per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1
  • One bone lesion on bone scan (tec99 or sodium fluoride [NaF] PET/CT, CT or MRI) for the bone-only cohort.

  • Histologically confirmed diagnosis of one of the following metastatic cohorts:

    • Small cell/ neuroendocrine carcinoma of the bladder (Cohort A)- All urothelial carcinomas with any amount of neuroendocrine differentiation (including small cell differentiation) will be included. If the tumor is purely neuroendocrine, metastasis from another site of origin should be clinically excluded
    • Adenocarcinoma of the bladder, or urachal adenocarcinoma, or bladder/urethra clear cell adenocarcinoma (Cohort B) - must be pure (per World Health Organization [WHO] definition), (i.e. urothelial carcinoma with glandular differentiation is not considered a pure adenocarcinoma
    • Squamous cell carcinoma of the bladder (Cohort C) - must be pure (i.e. urothelial carcinoma with squamous differentiation is not considered a pure squamous cell carcinoma)
    • Plasmacytoid urothelial carcinoma (Cohort D) - Tumor should show predominantly > or equal ~ 50% plasmacytoid histology (including all types of discohesive growth, such as tumors with signet-ring and/or rhabdoid features as well)
    • Any penile cancer (Cohort E)
    • Sarcomatoid renal cell carcinoma (Cohort F) - Tumor should be predominantly sarcomatoid ~ 50% (including rhabdoid differentiation) is also unclassified renal cell carcinomas (RCCs): all (assuming they are high grade with metastasis) malignant angiomyolipomas are allowed

    • Other miscellaneous histologic variants of the urothelial carcinoma, such as, but not limited to (Cohort G) : Micropapillary (Tumor should show predominantly > or equal 50% micropapillary architecture), giant cell, lipid-rich, clear cell and nested variants (Tumor should predominantly > or equal 50% show these features), large cell neuroendocrine carcinoma, lymphoepithelioma-like carcinoma and mixed patterns will be considered, as well as small cell neuroendocrine prostate cancer (Only treatment-naïve primary small cell of prostate with any amount of small cell component allowed. Post-treatment small cell prostatic carcinomas are not allowed), Malignant testicular Sertoli or Leydig cell tumors, and papillary and chromophobe RCC

      • Note: Translocation positive renal cell carcinoma patients are eligible. However, AREN1721 should be considered before this trial
    • Sarcomatoid urothelial carcinoma (Cohort H) - Tumor should show predominantly ~ 50% sarcomatoid differentiation
    • Renal medullary carcinoma (Cohort I) - Per World Health Organization (WHO) definition, ideally confirmed with immunostains
    • Bone-only metastatic GU tumors (non-prostate) (Cohort J) - All genitourinary histologies, except prostate are eligible
    • Renal Collecting Duct Carcinoma (Cohort K) - Per WHO definition (medullary involvement, predominant tubular morphology, desmoplastic stromal reaction, high grade cytology, infiltrative growth pattern, and absence of other renal cell carcinoma subtype or urothelial carcinoma)
    • Urethra carcinoma (Cohort L) - May be of any histology but if urothelial carcinoma then must be isolated to the urethra and not have metachronous or synchronous urothelial carcinoma of the bladder
  • H&E slides from diagnostic tumor tissue for retrospective central pathology review
• Patients may have received up to 2 systemic anti-cancer treatments or be treatment naive. Patients with small cell carcinoma should have received a platinum-based combination regimen either as neoadjuvant, adjuvant or first-line treatment). Patients in the bone-only cohort may be urothelial carcinoma histology but must receive standard cisplatin-based chemotherapy (if cisplatin-eligible)
• Age >= 18 years
• Patients must be able to swallow oral formulation of the tablets
• Karnofsky performance status >= 80%
• Absolute neutrophil count (ANC) >= 1,000/mcL
• Platelet count >= 75,000/mcL
• Total bilirubin =< 1.5 x upper limit of normal (ULN). For subjects with known Gilbert's disease or similar syndrome with slow conjugation of bilirubin, total bilirubin =< 3.0 mg/dL
• Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3.0 x institutional upper limit of normal (ULN) (or =< 5 x ULN for patients with liver metastases or Gilbert's disease)
• Creatinine =< 1.5 x upper limit of normal (ULN) OR creatinine clearance >= 40 mL/min/1.73 m^2 (calculated using the Chronic Kidney Disease Epidemiology [CKD-EPI] equation or Cockcroft-Gault formula) for patients with creatinine levels above institutional normal
• Hemoglobin >= 9 g/dL (transfusion of packed red blood cells [PRBCs] allowed)
• Serum albumin >= 3.2 g/dL
• Lipase and amylase =< 2.0 x ULN and no radiologic (on baseline anatomical imaging) or clinical evidence of pancreatitis
• Prior treatment with MET or VEGFR inhibitors is allowed. However, prior cabozantinib will not be allowed. Also, patients that have received both prior MET or VEGF and prior PD-1/PD-L1/CTLA-4 (sequentially or in combination) are also not allowed
• No prior treatment with any therapy on the PD-1/PD-L1 axis or anti- CTLA-4/CTLA-4 inhibitors with the exception of patients with "urothelial carcinoma" histology (cohorts D, H, J, L)
• Human immunodeficiency virus (HIV)-positive patients are eligible if on stable dose of highly active antiretroviral therapy (HAART), no clinically significant drug-drug interactions are anticipated with the current HAART regimen, CD4 counts are greater than 350 and viral load is undetectable
• Patients with rheumatoid arthritis and other rheumatologic arthropathies, Sjogren's syndrome and psoriasis controlled with topical medication only and patients with positive serology, such as antinuclear antibodies (ANA), anti-thyroid antibodies etc. are eligible but should be considered for rheumatologic evaluation for the presence of target organ involvement and potential need for systemic treatment
• Patients with vitiligo, endocrine deficiencies including thyroiditis managed with replacement hormones or medications (e.g. thyroiditis managed with propylthiouracil [PTU] or methimazole) including physiologic oral corticosteroids are eligible
• Patients who have evidence of active or acute diverticulitis, intra-abdominal abscess, and gastrointestinal (GI) obstruction, within 12 months are not eligible

• Women of childbearing potential must have a negative pregnancy test =< 7 days prior to registration

  • Women of childbearing potential include women who have experienced menarche and who have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are not postmenopausal. Post menopause is defined as amenorrhea >= 12 consecutive months. Note: women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, antiestrogens, ovarian suppression or any other reversible reason
• Pregnant women may not participate in this study because with cabozantinib, nivolumab, and ipilimumab have potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with cabozantinib, nivolumab, and ipilimumab, breastfeeding should be discontinued if the mother is treated with these agents
• The patient has received no cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (e.g., cytokines or antibodies) within 2 weeks before the first dose of study treatment

• The patient has received no radiation therapy:

  • To the lungs and mediastinum or abdomen within 4 weeks before the first dose of study treatment, or has ongoing complications, or is healing from prior radiation therapy
  • To brain metastasis within 3 weeks for whole-brain radiotherapy (WBXRT), and 2 weeks for stereotactic body radiation therapy (SBRT) before the first dose of study treatment
  • To the abdomen within 4 weeks before the first dose of study treatment, or has ongoing complications, or is healing from prior radiation therapy
  • To any other site(s) within 2 weeks before the first dose of study treatment
• The patient has received no radionuclide treatment within 6 weeks of the first dose of study treatment
• The patient has received no prior treatment with a small molecule kinase inhibitor within 14 days or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatment
• The patient has received no prior treatment with hormonal therapy within 14 days or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatment. Subjects receiving gonadotropin-releasing hormone (GnRH) agonists and antagonists are allowed to participate
• The patient has not received any other type of investigational agent within 14 days before the first dose of study treatment
• The patient must have recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade 1 from toxicity due to all prior therapies except alopecia, neuropathy and other non-clinically significant adverse events (AEs) defined as lab elevation with no associated symptoms or sequelae
• The patient may not have active brain metastases or epidural disease. Patients with brain metastases previously treated with whole brain radiation or radiosurgery who are asymptomatic and do not require steroid treatment for at least 2 weeks before starting study treatment are eligible. Neurosurgical resection of brain metastases or brain biopsy is permitted if completed at least 3 months before starting study treatment. Baseline brain imaging with contrast-enhanced CT or MRI scans for subjects with known brain metastases is required to confirm eligibility
• No concomitant treatment with warfarin. Aspirin (up to 325 mg/day), thrombin or factor Xa inhibitors, low-dose warfarin (=< 1 mg/day), prophylactic and therapeutic low molecular weight heparin (LMWH) are permitted

• No chronic concomitant treatment with strong CYP3A4 inducers (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, and St. John's wort) or strong CYP3A4 inhibitors

  • Because the lists of these agents are constantly changing, it is important to regularly consult medical reference texts such as the Physicians' Desk Reference may also provide this information. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product

• The patient has not experienced any of the following:

  • Clinically-significant gastrointestinal bleeding within 6 months before the first dose of study treatment
  • Hemoptysis of >= 0.5 teaspoon (2.5 mL) of red blood per day within 1 months before the first dose of study treatment
  • Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment
• The patient has no tumor invading any major blood vessels
• The patient has no evidence of tumor invading the GI tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinib. Patients with rectal tumor masses are not eligible

• The patient has no uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:

  • Cardiovascular disorders including:

    • Congestive heart failure (CHF): New York Heart Association (NYHA) class III (moderate) or class IV (severe) at the time of screening.
    • Concurrent uncontrolled hypertension defined as sustained blood pressure (BP) > 150 mm Hg systolic, or > 90 mm Hg diastolic despite optimal antihypertensive treatment within 7 days of the first dose of study treatment
    • The subject has a corrected QT interval calculated by the Fridericia formula (QTcF) > 500 ms within 28 days before randomization. Note: if initial QTcF is found to be > 500 ms, two additional electrocardiograms (EKGs) separated by at least 3 minutes should be performed. If the average of these three consecutive results for QTcF is =< 500 ms, the subject meets eligibility in this regard
    • Any history of congenital long QT syndrome

    • Any of the following within 6 months before registration of study treatment:

      • Unstable angina pectoris
      • Clinically-significant cardiac arrhythmias (patients with atrial fibrillation are eligible)
      • Stroke (including transient ischemic attack [TIA], or other ischemic event)
      • Myocardial infarction
      • Cardiomyopathy

  • No significant gastrointestinal disorders particularly those associated with a high risk of perforation or fistula formation including:

    • Any of the following that have not resolved within 28 days before the first dose of study treatment:

      • Active peptic ulcer disease
      • Acute diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, or malabsorption syndrome

    • None of the following within 2 years before the first dose of study treatment:

      • Abdominal fistula or genitourinary fistula
      • Gastrointestinal perforation
      • Bowel obstruction or gastric outlet obstruction
      • Intra-abdominal abscess. Note: Complete resolution of an intra-abdominal abscess must be confirmed prior to initiating treatment with cabozantinib even if the abscess occurred more than 2 years before the first dose of study treatment
  • Disorders associated with a high risk of fistula formation including percutaneous endoscopic gastrostomy (PEG) tube placement are not eligible

  • No other clinically significant disorders such as:

    • Severe active infection requiring IV systemic treatment within 14 days before the first dose of study treatment
    • Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment
    • History of organ or allogeneic stem cell transplant
    • Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment (for asymptomatic patients with an elevated thyroid-stimulating hormone [TSH], thyroid replacement may be initiated if clinically indicated without delaying the start of study treatment)

  • No history of major surgery as follows:

    • Major surgery within 3 months of the first dose of cabozantinib; however, if there were no wound healing complications, patients with rapidly growing aggressive cancers, may start as soon as 6 weeks if wound has completely healed post-surgery
    • Minor surgery within 1 month of the first dose of cabozantinib if there were no wound healing complications or within 3 months of the first dose of cabozantinib if there were wound complications excluding core biopsies and mediport placement
    • Complete wound healing from prior surgery must be confirmed before the first dose of cabozantinib irrespective of the time from surgery
• No history of severe hypersensitivity reaction to any monoclonal antibody
• No evidence of active malignancy, requiring systemic treatment within 2 years of registration
• No history of allergic reactions attributed to compounds of similar chemical or biologic composition to cabozantinib, nivolumab, ipilimumab or other agents used in study
• No positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection. If HBV sAG is positive, subsequent ribonucleic acid (RNA) polymerase chain reaction (PCR) must be negative
• No patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids. These include, but are not limited to patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome should be excluded because of the risk of recurrence or exacerbation of disease

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Treatment (cabozantinib, nivolumab, ipilimumab); Patients receive cabozantinib PO QD on days 1-21 of cycles 1-4 and on days 1-28 of subsequent cycles. Patients also receive nivolumab IV over 30 minutes on day 1 and ipilimumab IV over 90 minutes on day 1 of cycles 1-4. Patients then receive nivolumab IV over 30 minutes on day 1 of subsequent cycles. Treatment repeats every 21 days for cycles 1-4 and every 28 days for subsequent cycles for 2 years in the absence of disease progression or unacceptable toxicity. Patients may undergo echocardiography during screening and undergo CT or MRI, bone scan and blood and urine sample collection throughout the trial and may undergo PET/CT throughout the trial.

Biological: Nivolumab; Given IV; Other Names: BMS-936558; MDX-1106; NIVO; ONO-4538; Opdivo; CMAB819; Nivolumab Biosimilar CMAB819; MDX 1106; MDX1106; BMS 936558; ABP 206; Nivolumab Biosimilar ABP 206; BCD-263; Nivolumab Biosimilar BCD-263; BMS936558; ONO 4538; ONO4538; Procedure: Magnetic Resonance Imaging; Undergo MRI; Other Names: MRI; Magnetic Resonance; Magnetic Resonance Imaging Scan; Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance; MR; MR Imaging; MRI Scan; NMR Imaging; NMRI; Nuclear Magnetic Resonance Imaging; Magnetic Resonance Imaging (MRI); sMRI; Magnetic resonance imaging (procedure); MRIs; Structural MRI; Biological: Ipilimumab; Given IV; Other Names: Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody; BMS-734016; Ipilimumab Biosimilar CS1002; MDX-010; MDX-CTLA4; Yervoy; MDX010; BMS734016; BMS 734016; MDX 010; Procedure: Positron Emission Tomography; Undergo PET/CT scan; Other Names: Medical Imaging, Positron Emission Tomography; PET; PET Scan; Positron Emission Tomography Scan; Positron-Emission Tomography; PT; Positron emission tomography (procedure); Drug: Cabozantinib S-malate; Given PO; Other Names: BMS-907351; Cabometyx; Cometriq; XL-184; XL184; XL 184; Procedure: Biospecimen Collection; Undergo blood and urine sample collection; Other Names: Biological Sample Collection; Biospecimen Collected; Specimen Collection; Sample Collection; Procedure: Bone Scan; Undergo bone scan; Other Names: Bone Scintigraphy; Procedure: Computed Tomography; Undergo CT and/or PET/CT scan; Other Names: CT; CAT; CAT Scan; Computed Axial Tomography; Computerized Axial Tomography; Computerized Tomography; CT Scan; tomography; Computerized axial tomography (procedure); Computerized Tomography (CT) scan; Diagnostic CAT Scan; Diagnostic CAT Scan Service Type; Procedure: Echocardiography Test; Undergo echocardiography; Other Names: Echocardiography; EC

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Objective response rate (ORR)	An objective response is defined as a confirmed complete response (CR) or partial response (PR) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. A confirmed tumor response is defined to be either a CR or PR noted as the objective status on 2 consecutive evaluations at least 4 weeks apart. Will be estimated by the number of confirmed objective responses divided by the total number of evaluable patients. Confidence intervals for the true ORR will be calculated.	Up to 5 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Duration of response	Defined for all evaluable patients who have achieved an objective response as the date at which the patient's earliest best objective status is first noted to be either a CR or PR to the earliest date progression is documented.	From time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, assessed up to 5 years
Progression-free survival (PFS)	The median its 95% confidence interval will be determined and will be summarized using the Kaplan-Meier estimator.	From start of treatment to time of progression or death, whichever occurs first, assessed up to 5 years
Overall survival	The median its 95% confidence interval will be determined and will be summarized using the Kaplan-Meier estimator.	Up to 5 years
Clinical benefit rate (CBR)	A confirmed clinical benefit is defined to be either a CR or PR noted as the objective status on 2 consecutive evaluations at least 4 weeks apart or a confirmed stable disease at two consecutive tumor assessments at least 3 months apart. The CBR will be estimated by the number of patients with confirmed clinical benefit divided by the total number of evaluable patients. Confidence intervals for the true CBR will be calculated using exact binomial confidence intervals.	Up to 5 years
Incidence of adverse events (AE)	Will be assessed using Common Terminology Criteria for Adverse Events version 5.0. The maximum of a particular AE will be determined for each patient. Tables will summarize the number and relative frequency of patients observing an AE as well as the number and relative frequency of patients experiencing any AE of grade 3 or greater.	Up to 5 years

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Effects of treatment in patients with bone-only disease	The bone-only tumor patients will be evaluated in an exploratory fashion (if no RECIST measurements are available). A maximum of 15 patients with bone-only disease will be enrolled and evaluated using PFS for a descriptive analysis of the effect of treatment.	Up to 5 years

Collaborators and Investigators

• Sponsor: National Cancer Institute (NCI)
• Investigators: Principal Investigator: Andrea B Apolo, Alliance for Clinical Trials in Oncology

Publications and helpful links

General Publications

• Girardi DM, Niglio SA, Mortazavi A, Nadal R, Lara P, Pal SK, Saraiya B, Cordes L, Ley L, Ortiz OS, Cadena J, Diaz C, Bagheri H, Redd B, Steinberg SM, Costello R, Chan KS, Lee MJ, Lee S, Yu Y, Gurram S, Chalfin HJ, Valera V, Figg WD, Merino M, Toubaji A, Streicher H, Wright JJ, Sharon E, Parnes HL, Ning YM, Bottaro DP, Cao L, Trepel JB, Apolo AB. Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy. Clin Cancer Res. 2022 Apr 1;28(7):1353-1362. doi: 10.1158/1078-0432.CCR-21-3726.

Study record dates

Study Major Dates

• Study Start (Actual): May 13, 2019
• Primary Completion (Estimated): February 28, 2027
• Study Completion (Estimated): February 28, 2027

Study Registration Dates

• First Submitted: March 6, 2019
• First Submitted That Met QC Criteria: March 6, 2019
• First Posted (Actual): March 7, 2019

Study Record Updates

• Last Update Posted (Actual): June 11, 2026
• Last Update Submitted That Met QC Criteria: June 10, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Urogenital Diseases; Genital Diseases; Genital Neoplasms, Male; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Prostatic Diseases; Male Urogenital Diseases; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Neoplasms by Histologic Type; Neoplasms, Glandular and Epithelial; Adenocarcinoma; Urologic Neoplasms; Carcinoma; Kidney Neoplasms; Urinary Bladder Diseases; Urethral Diseases; Penile Diseases; Prostatic Neoplasms; Carcinoma, Renal Cell; Urinary Bladder Neoplasms; Carcinoma, Transitional Cell; Urethral Neoplasms; Urogenital Neoplasms; Penile Neoplasms; Urachal adenocarcinoma; Amino Acids, Peptides, and Proteins; Proteins; Investigative Techniques; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Biological Factors; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Serum Globulins; Globulins; Chemistry Techniques, Analytical; Spectrum Analysis; Receptors, Cell Surface; Membrane Proteins; Antigens; Antigens, Surface; Biomarkers; Receptors, Immunologic; Antigens, Differentiation, T-Lymphocyte; Antigens, Differentiation; Immune Checkpoint Proteins; Costimulatory and Inhibitory T-Cell Receptors; Nivolumab; Ipilimumab; Specimen Handling; Magnetic Resonance Spectroscopy; cabozantinib; CTLA-4 Antigen
• Other Study ID Numbers: NCI-2019-01266 (Registry Identifier: CTRP (Clinical Trial Reporting Program)); U10CA180821 (U.S. NIH Grant/Contract); A031702 (Other Identifier: CTEP)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No